Quarterlytics / Industrials / Eden Innovations Ltd / FY2020 Annual Report

Eden Innovations Ltd
Annual Report 2020

EDE · ASX Industrials
Claim this profile
Ticker EDE
Exchange ASX
Sector Industrials
Industry
Employees 11-50
← All annual reports
FY2020 Annual Report · Eden Innovations Ltd
Loading PDF…
Annual Report 
for the Year Ended 30 June 2020

CONTENTS

Highlights 

Corporate Directory 

Review of Operations 

Directors’ Report 

Auditors Independence Declaration 

Consolidated Statement of Profit or Loss  
and Other Comprehensive Income 

Consolidated Statement of Financial Position 

Consolidated Statement of Changes in Equity 

Consolidated Statement of Cash Flows 

Notes to the Financial Statements 

Directors’ Declaration 

Independent Auditor’s Report 

Additional Information for Listed Public Companies 

2

4

5

13

19

20

21

22

23

24

41

42

45

1

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEHIGHLIGHTS DURING THE 2019-2020 FINANCIAL YEAR

SALES

EdenCrete® 

OptiBlend® 

Total 

Sales for year ended  
30 Jun 2020, A$000’s

Sales for year ended  
30 Jun 2019, A$000’s

Sales % Change

1,498

929

2,427

1,615

720

2,335

-7%

29%

4%

EDENCRETE®
¬  EdenCrete® sales during the year decreased by 7% 

compared to the prior year, due primarily to the significant 
impact of COVID-19 on business activity around the world. 
However, the impact of COVID-19 on EdenCrete® sales is 
starting to wane and sales are projected to increase over 
the remainder of the calendar year.

USA
¬  In spite of the significant impact of the COVID-19 

pandemic, encouraging growth has still taken place over 
FY2020 in the number of US States where EdenCrete® 
sales and/or trials are occurring: 

-  During the year, sales of EdenCrete® products 
occurred in Georgia, Colorado, New York, South 
Carolina, Ohio and Utah.

-  During the year, trials with potential customers took 

place, are underway, or are planned, in Georgia, 
Colorado, New York, South Carolina, Idaho, Ohio, Utah, 
Illinois, Indiana, Wisconsin, Oklahoma, Florida and 
Pennsylvania. 

¬  Restructuring of US sales team occurred with 

the appointment of four commission-only sales 
representatives to supplement the existing sales team.

Georgia
¬  Completed the second GDOT / Federal (FHWA) funded 
project using EdenCrete® for pavement repairs on 
11 miles of highway, requiring over US$500,000 of 
EdenCrete®. 

¬  Two such FHWA jointly funded projects are anticipated 

during FY 2021.

¬  Following the successful completion of a 12 months’ 
field trial, EdenCrete® was accepted for use on GDOT 
construction and maintenance projects for mainline 
paving.

¬  The first GDOT bridge trial of EdenCrete® concrete.
¬  Three Georgia ready-mix operators developing or selling 

proprietary EdenCrete® mixes.

¬  Georgia Port Authority (GPA) field trial of EdenCrete® 

concrete delivered highly encouraging results including:
-  Compressive strength achieved at 28 days of 10,010 
psi exceeded by 100% the required minimum 28 days 
strength of 5,000psi. 

-  Compressive strength achieved at 28 hours (5,720 

psi) exceeded the required minimum to re-open the 
section (4,000psi) by 43%, approximately 48 hours 
earlier than is usually the case.

¬  Following the successful completion of this trial 

EdenCrete® was named in first GPA project (500 CY of 
concrete) – the date for the project is not yet determined 
and further trials are planned including chloride 
permeability, ASR mitigation, freeze/thaw protection, 
chemical scaling resistance and shrinkage reduction.
¬  Eden commenced developing its own marine concrete 

mix for use in future port applications in the USA.

Colorado
¬  8 ready-mix companies, that between them have 

EdenCrete® dispensing systems installed at 13 different 
plant sites, now regularly using EdenCrete® products 
(and including 3 ready-mix companies with 4 plants that 
started using EdenCrete® in FY 2020).

¬  EdenCrete®, since late 2018, has been and continues 
to be used in a range of shotcrete applications on the 
10 mile, Colorado DOT Central 70 project on Interstate 
Highway I-70.

¬  A number of local government authorities, contractors 
and property owners are now specifying EdenCrete® 
on a repeat basis for a range of projects, including on 
nine separate repair projects at a professional sporting 
stadium.

¬  Town of Breckenridge has used EdenCrete® in a number 

of projects since late 2019.

New York 
¬  First order for EdenCrete®Pz received from New York 

ready-mix company for use in low-midrise construction 
and bulk dispensing system installed in their plant.

¬  Repeat order received after the end of the financial year.

2

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDESouth Carolina 
¬  Growing demand for EdenCrete® in industrial flooring 

SOUTH KOREA 
¬  Trials with a major ready-mix company are continuing

applications in South Carolina.

¬  EdenCrete® ordered by contractor for an outdoor 

concrete storage area for large, industrial tyres at South 
Carolina plant owned by an international tyre company.

¬  A repeat order received from same contractor for 

US$120,000 of EdenCrete® for inclusion in 200,000 
square ft. industrial storage area for same international 
tyre company.

¬  Three orders received from a second large company for 

warehouse floors in South Carolina.

Ohio
¬  First order received from an Ohio-based ready-mix 

company and bulk dispensing system installed in their 
plant for future sales.

Utah
¬  Two ready-mix plants and one shotcrete operator 

installed storage and dispensing equipment for inclusion 
of EdenCrete® in their standard concrete mixes.

NTPEP Approvals Obtained
¬  NTPEP Approval of EdenCrete® and EdenCrete®Pz 

received, opening the way for approvals by all US DOTs.

DOT APPROVALS- Status 
¬  20 State DOTs have approved EdenCrete® and 14 have 

approved EdenCrete®Pz

AUSTRALIA AND NEW ZEALAND
¬  Eden received and dispatched the first Australian 

EdenCrete® order for Parchem. 

¬  Initial regulatory approval to import EdenCrete® into 

Australia for trials received by Parchem. Final approval 
hoped to be received before the end of October 2020.
¬  Commercial trials have commenced in Australia - 40 trial 

requests received to date.

INDIA
¬  Eden has, since the end of the financial year, received its 
first order from Godrej Ready Mix, a division of the highly 
respected, Godrej Group of companies, with which Eden 
has been developing a range of EdenCretePz® concrete 
mixes with high fly ash content.

EUROPE 
¬  Extensive trials of EdenCrete® products by a large 

European construction company commenced in July 
2019 and were scheduled to be completed in the first half 
of 2020. However due to COVID 19, the trials were shut 
down from February 2020 until August 2020 and at the 
date of this report these trials have recommenced, with 
finalisation anticipated before the end of CY2020.

US EDENCRETE® PATENT ALLOWED
¬  US patent application no. 15/597,198 allowed - includes 
24 claims directed to the production of the EdenCrete® 
family of products.

OPTIBLEND®
¬  Sales of OptiBlend® Dual Fuel Systems rose 29% during 
the year, to approx. A$929,000, with continued market 
interest in USA and India and emerging interest from 
Nigeria.

¬  Appointment of new commission-only OptiBlend® sales 

representatives in USA and India. 

EDENPLASTTM
¬  US Patent No. 10,472,240 issued - includes 16 claims 
directed to the production of the EdenPlast® family of 
products. 

¬  A Japanese plastics company expressed an interest in 

testing EdenPlast® and a concentrated master batch has 
been prepared in Australia and sent to Japan for testing 
by the Japanese company. 

CORPORATE
¬  Eden completed a Share Purchase Plan (SPP), raising 

A$2,908,000 before costs, through the issue of 
58,160,000 Shares at 5 cents per share.

¬  Eden US secured US$3 million of debt financing for 
working capital, secured against its US properties.
¬  Eden US also received a US Government backed loan 

of US$634,000, under the US Government’s COVID-19 
stimulus package, which is likely to become a grant and 
not be repayable provided certain conditions related to 
continued employment are met.

¬  New executive appointment in Eden Innovations LLC 

(Eden US). 

¬  Since the end of FY2020, Eden completed a well-

supported Share Purchase Plan (SPP) that closed on 
23 July 2020, with shareholders subscribing a total of 
A$4,244,897 for 151,603,497 shares.

3

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDECORPORATE DIRECTORY

DIRECTORS:
Gregory H Solomon  LLB  (Executive Chairman)
Douglas H Solomon  BJuris LLB (Hons)  (Non-Executive)
Lazaros Nikeas B.A. (Non-Executive)
Stephen D Dunmead B.Sc., M.Sc., Ph.D. (Non-Executive) 

COMPANY SECRETARY:
Aaron P Gates BCom CA AGIA

REGISTERED OFFICE:
Level 15
197 St Georges Terrace
Perth
Western Australia  6000
Tel +61 8 9282 5889
Fax +61 8 9282 5866
Email: mailroom@edeninnovations.com.au
Website: www.edeninnovations.com 

SOLICITORS:
Solomon Brothers
Level 15
197 St Georges Terrace
Perth  WA  6000

AUDITORS:
Nexia Perth Audit Services Pty Ltd 
Level 3
88 William Street
Perth  WA  6000

SHARE REGISTRY:
Advanced Share Registry Services
110 Stirling Highway
Nedlands  WA   6009 

STOCK EXCHANGE LISTING:
ASX Code: EDE   (ordinary shares) EDEOB (8 cent listed options)

Quotation has been granted for all the ordinary shares and issued EDEOB options of the 
company on all Member Exchanges of the Australian Securities Exchange Limited.

4

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEREVIEW OF OPERATIONS

IMPACT OF COVID-19

The COVID-19 pandemic has, for more than six months, 
had a significant impact on sales and trials of EdenCrete® 
products, both in the USA and in a number of other 
countries, but at the date of this report, this impact on 
EdenCrete® sales is starting to wane in the USA, as well as 
Europe and India.

For example, the significant European construction 
company that commenced in July 2019 an extensive 
testing programme with EdenCrete® products in a range 
of concrete mixes, and which was forced to shut all 
research operations for over six months from early 2020, 
has now at the date of this report re-opened its research 
division and is about to commence the final phase of this 
testing programme that is expected to be completed in 
CY2020. 

Similarly, in India, an extensive trial project using 
EdenCrete®Pz by a large construction company was 
completed in early February 2020, only for all projects 
to then be suspended due to national lockdown 
requirements. However, the company has, after a delay of 
more than six months, issued its first purchase order for 
EdenCrete®Pz. 

Further, since the end of the financial year, Eden received 
its first commercial order for EdenCrete® products from 
Israel, to be used in commercial trials. This followed a 
similar delay after initial trials in Israel were completed in 
February 2020.

However, throughout this whole period, Eden has been 
very fortunate in that its US operations in Colorado, 
including both testing as well as production of all its 
products, have been able to continue operating, with staff 
observing social distancing and other policies that were 
implemented, with no delays in production or testing 
occurring. At the same time, none of Eden’s US staff or 
their immediate families have tested positive for the 
COVID-19 virus.

SALES AND MARKETING PROGRESS 

During FY2020 year, total EdenCrete® sales (A$1,498,121) 
were achieved, which is slightly lower than in FY2019 
(A$1,614,546). The primary cause of this has been the 
impact of COVID-19 on Eden’s current and potential 
customers. However, this downward trend in sales over 
the past six months is finally starting to reverse and is 
not anticipated to be reflective of the longer-term sales 
trajectory. 

The restructuring and expansion of the US sales force, 
the continuing growth in the number US EdenCrete® 
customers, the increase in the number of US states 
where sales and/or trials are occurring, supported by the 
extension in the geographic footprint of EdenCrete® into 

a number of other countries where EdenCrete® trials are 
occurring, are expected to help drive increased sales in 
the remainder of FY2021. 

OptiBlend® sales are also anticipated to increase over 
the coming periods as new commission-only sales 
representatives, two of whom have been appointed, help 
drive an increase in OptiBlend® sales in both India and 
USA.

More details of the progress made during the year are 
detailed below.

EDENCRETE®

USA - GROWTH OF US EDENCRETE® FOOTPRINT

Regular sales to repeat customers continued in a number 
of US States, for a range of projects including building 
construction and maintenance, driveways, industrial 
flooring, shotcrete applications, and highway repairs. 
During the year, sales of EdenCrete® products have 
occurred in Georgia, Colorado, New York, South Carolina, 
Ohio and Utah.

In addition, during the year, trials with new, and including a 
number of potentially significant, customers that operate 
in a range of market sectors, took place, are presently 
underway, or are being planned in Georgia, Colorado, New 
York, South Carolina, Idaho, Ohio, Utah, Illinois, Indiana, 
Wisconsin, Oklahoma, Florida and Pennsylvania. 

Experience over the past three years has shown that a 
significant proportion of the growth in EdenCrete® sales 
over this time has occurred following successful trials or 
projects, with news of the successes often being passed 
on to new customers by various means, including by 
contractors who undertook the successful project.

US EDENCRETE® SALES FORCE

To service the increasing US interest and help accelerate 
the growth in sales, the structure of the US sales team 
has been reviewed and two or three new sales people are 
planned. To date one further member of the sales team 
has been appointed.

Eden has also appointed a number of new sales 
representatives that are selling EdenCrete® products on a 
commission-only basis. To date four sales representatives 
have been appointed, providing sales coverage in Texas, as 
well as in the mid-west, south-east and north-east areas 
of the US.

5

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEUS STATE DOT APPROVALS

To date 20 State Departments of Transportation (DOTs) 
have approved EdenCrete® and 14 have approved 
EdenCrete®Pz. The 20 State DOTs that have approved 
EdenCrete® are:

Alabama, Alaska, Arkansas, California, Colorado, Georgia, 
Kentucky, Louisiana, Maine, Massachusetts, Mississippi, 
North Carolina, Oklahoma, Oregon, South Carolina, 
Tennessee, Texas, Vermont, Virginia and West Virginia 

These 20 States between them have approximately:

•  48% of the total US population; 

•  69,971 bridges that are structurally deficient or 

functionally obsolete; 

•  47% of the total number of such defective bridges in 

the USA; and

•  51% of the total US land area.

GEORGIA INFRASTRUCTURE

Second GDOT/FHWA funded highway repair project

The second, jointly funded by the Federal Highway 
Administration (FHWA) (80%) and the Georgia Department 
of Transportation (GDOT) (20%), highway repair project 
that included EdenCrete®, commenced late in September 
2019 and finished in February 2020. 

The US$17.4 million project involved the replacement of 
numerous sections of concrete pavement along 17.35 
miles of Interstate Highway I-285 and State Road SR 
407. Initially the project was estimated to involve the 
replacement of 5,146 cubic yards of concrete, requiring 
10,292 gallons of EdenCrete® worth US$257,300.  

As happened with the first FHWA jointly funded project, where 
the initial scope of the project was expanded by almost 
40%, by the end of the second project EdenCrete worth 
approximately US$550,000 was required to complete it.

Two such FHWA jointly funded projects are anticipated to 
take place in Georgia during the remainder of FY 2021.

GDOT funded repair projects

During the year, four State funded repair projects requiring 
approximately US$107,500 worth of EdenCrete® were 
advertised for tender but due to delays, these projects did 
not occur, and are now scheduled to take place sometime 
in FY2021. 

GDOT - First EdenCrete® bridge trial in Georgia 

The first EdenCrete® bridge trial with GDOT commenced 
on a bridge across Little River, with EdenCrete® being 
tested in new concrete decking. The construction of the 
new decking commenced in November 2019 and was 
completed in December 2019. 

The fresh properties of the EdenCrete® concrete satisfied 
all the required specifications. Further, the EdenCrete® 
concrete was tested for compressive strength and flexural 
strength over a 28 day period, delivering the following 
positive results: 

After 24 Hours - Compressive strength 
(12% over design)

After 72 Hours - Compressive strength 
(37% over design) 

After 28 Days - Compressive strength  
(70% over design)

After 28 Days - Flexural strength 
(41% over design) 

2767 PSI

4790 PSI

6787 PSI

915 PSI

The performance of the concrete decking will be 
monitored for the period of the trial, which could be up to 
2 years. However, this monitoring period may be reduced 
by GDOT if it is satisfied with the performance levels that 
are achieved in other existing bridge trials of EdenCrete® 
that are being conducted by other DOTs, some of which 
have already been underway for more than a year. 

GDOT Mainline Paving

Following the successful completion of a 12 months 
field trial, EdenCrete® was approved for use on GDOT 
construction and maintenance projects for mainline 
paving. The trial took place on a state highway in Comer 
County, Georgia and involved adding EdenCrete® into 80 
yards of a new, two lane concrete highway (see Figure 1).

Figure 1. Completed section of highway with added EdenCrete®.

The successful 12 months’ evaluation undertaken by 
GDOT, that only commenced after the new roadway was 
opened to traffic, resulted in the GDOT New Products 
Evaluation Committee accepting EdenCrete® for use 
in the construction and maintenance of new concrete 
pavements under GDOT Specifications Sections 430 and/
or 439. 

6

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEThis successful outcome opens the way for the possible 
future use of EdenCrete® in the construction of new roads 
and highways in Georgia. The total annual budget for new 
roads (both asphalt and concrete) in Georgia currently 
exceeds US$700 million per annum. 

Georgia Port Authority - Port of Savannah

During the year, the Port of Savannah (part of the Georgia 
Port Authority) conducted a trial of EdenCrete® in a section 
concrete on one of its wharves that is subject to a very 
heavy loading and abrasion from the wheels of the large 
container cranes moving back and forth as containers are 
loaded and unloaded (known as the “runway”) (see Figure 
2). The concrete runways at the port are exposed to both a 
salty environment and extreme rolling loads and abrasive 
wear that cause cracking, abrasion and breakdown of the 
concrete, requiring the worn concrete to be frequently 
ripped up and replaced under a highly disruptive, scheduled 
maintenance programme.

The trial was undertaken and all the laboratory trials 
of the compressive strength of the concrete that 
was used collectively showed that the EdenCrete® 
concrete comfortably exceeded the minimum strength 
requirements.  The trial involved the monitoring of the 
longer term performance of the concrete. This trial and 
review of performance was successfully completed during 
the first half of 2020. Following which EdenCrete® was 
named in specifications for its first commercial GPA 
project (500 CY of concrete), the date for which has not 
yet been determined.

Further trials for GPA are also planned, including chloride 
permeability, ASR mitigation, freeze/thaw protection, 
chemical scaling resistance and shrinkage reduction. 
Development of specialised EdenCrete® marine mix is 
currently being undertaken at Eden’s Colorado laboratory. 

The Port of Savannah, the third busiest container port in 
the USA, is planning to nearly double its capacity over the 
next 8 years, and along with opportunities at other ports 
in Georgia as well as along both the US Atlantic coast 
and the Gulf of Mexico, offers great potential for future 
EdenCrete® sales.

In preparation for this, Eden has been developing for 
several months its own EdenCrete® marine concrete 
mix which it hopes will be approved and specified as the 
concrete mix design in suitable projects in ports around 
the USA in coming years.

Three Ready-Mix developing or selling proprietary 
EdenCrete® concrete mixes

During the year Eden secured its first Georgia based 
ready-mix operator that had developed a proprietary 
concrete mix incorporating EdenCrete® products, that it is 
now marketing this concrete mix on a regular basis. 

This follows similar success in Colorado, where after the 
development by one ready-mix operator of an EdenCrete® 
enhanced concrete mix, others followed and now 8 ready-
mix operators have proprietary EdenCrete® mixes, leading 
to rapidly increasing EdenCrete® sales in Colorado, which 
is hoped will also occur in Georgia and adjoining South 
Carolina.

COLORADO

Continued growth of EdenCrete® sales in Colorado

During the year, usage and sales of EdenCrete® products 
in Colorado continued to rise in spite of obstacles raised 
by COVID-19. Currently there are 8 ready-mix operators 
and 4 shotcrete operators in Colorado using EdenCrete® 
on a regular basis. 

The 8 ready-mix companies, between them, have 
EdenCrete® dispensing systems installed at 13 different 
plant sites, that regularly use EdenCrete® products. These 
8 companies also include 3 ready-mix companies (with 
4 plants between them) that only commenced using 
EdenCrete® in FY 2020.

Further, as a result of the improved performance and 
durability delivered by EdenCrete® products, a growing 
number of government bodies, contractors and property 
owners are now regularly specifying EdenCrete® on a 
repeat basis for a range of projects, some examples of 
which are as follows:

Figure 2. Container crane at Port of Savannah showing wheels 
on “runway”.

7

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEREVIEW OF OPERATIONS (Continued)

Colorado DOT Central 70 Project

Since late 2018, EdenCrete® has been continuously used 
in shotcrete on the Colorado DOT Central 70 project on 
the Interstate Highway I-70. This project involves the 
reconstruction of 10 miles of the I-70, including sinking 
part of the highway. The EdenCrete® shotcrete mix is used 
in buttress and retaining walls along the highway (see 
Figures 3-5). The project is estimated to require 6,000-
10,000 cubic yards of shotcrete. EdenCrete® is added at 
0.5 gallons per cubic yard. 

Figure 3. Retaining wall along Central 70 project constructed 
using EdenCrete®shotcrete.

Figure 5. Retaining wall constructed under bridge using 
EdenCrete® on Central 70 project.

Professional Sporting Stadium

During the year EdenCrete® was purchased for use in a 
number of separate, often reasonably small, concrete 
repair projects at different parts of a professional sporting 
stadium (see Figures 6-13). The collective outcome from 
the repeated successful performance of EdenCrete® in 
these various situations (as well as others) has opened 
up sporting stadiums and arenas as a new EdenCrete® 
market that Eden is now actively targeting.

Figure 4. Retaining wall being constructed along Central 70 
project using EdenCrete® shotcrete.

Figure 6. Interior Corridors-  3 inch thick EdenCrete® concrete 
overlay repair on a drainage system and suspended deck.

8

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
Figure 7. Perimeter Facilities - 5- 6 inch thick, full-depth  
slab repair.

Figure 11.  Exterior Corridors – 5-6 inch thick full-depth slab.

Figure 8. Interior Corridors- 4 inch thick overlay on  
suspended slab.

Figure 12. Freight Access Ramps- 8 inch thick slab on grade 
using 5000psi (35MPa) structural concrete.

Figure 9. Access for Ticket Turnstiles – 5-6 inch thick  
full-depth slab.

Figure 13. Steel Bollard security Screening Areas – 6 inch thick 
full-depth slab.

Town of Breckenridge

During the year, the Town of Breckenridge has specified 
that EdenCrete® be included in a number of projects 
undertaken by the Town since early in 2020. This follows 
a successful result from an initial project involving 
EdenCrete® that was carried out early in 2020. 

9

Figure 10. Centres for Health, Nutrition and Physical Therapy- 
EdenCrete® used in shotcrete for walls.

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
 
REVIEW OF OPERATIONS (Continued)

earlier South Carolina project, as well as in several other 
similar projects. The contractor won the competitive tender 
process for the new project, with a bid including EdenCrete®, 
to construct a new 200,000 square foot (18,500 square 
metres) external concrete industrial storage area that was 
to be subject to heavy-duty wear at an industrial plant (see 
Figure 15).

NEW YORK 

EdenCrete®Pz – First Sale into New York Market

During the year Eden received its first order for 
EdenCrete®Pz in New York from United Transit, a ready–
mix operator, for use in concrete that is used in the 
construction of low-mid-rise buildings (see Figure 14). A 
bulk tank and dispending system was installed, enabling 
dosing of EdenCrete®Pz into the concrete during batching 
in the same automated manner as other components are 
added. 

Subsequent to the first order, re-supply was not possible 
for six months due to COVID -19 restrictions. Once these 
restrictions were eased, a second delivery of EdenCrete® 
was made towards the end of June 2020.

Figure 15.  200,000 square foot Industrial slab being poured.

This order supplied a combination of EdenCrete® and 
EdenCretePz® to create tougher, more durable concrete 
that is better able to handle both the heavy loading, and 
the constant abrading forces from heavy forklift traffic. The 
engineering firm engaged on the project approved a number 
of design specifications for the concrete, including a mix 
incorporating EdenCrete® and EdenCrete Pz®. 

Significantly, due to the performance benefits delivered by 
the EdenCrete® products, the engineering firm approved a 
reduction by 7.5% in the design thickness of the EdenCrete® 
concrete slab, compared with other mix designs, whilst still 
meeting the required performance levels.

The successful contractor won the tender with a bid using 
an EdenCrete® enhanced concrete, against a competitive 
bid from another contractor that proposed a mix design 
involving metallic fibres to achieve the required performance 
specification

Three similar industrial flooring projects in South Carolina 
have occurred with a second large company 

As a result of subsequent recommendations by the 
contractor involved in these earlier projects in South 
Carolina, EdenCrete®  trials were conducted with another 
large company in South Carolina and a positive outcome 
from these trials has now resulted in Eden having receiving 
three separate orders for EdenCrete® to be used in three 
similar warehouse projects in South Carolina for this second 
company (see Figure 16).

OHIO

During the year the first order was received from an Ohio 
based ready-mix company and a bulk tank and dispensing 
system was installed in their plant. This represents the first 
sale into Ohio.

10

Figure 14. United Transit concrete being supplied to a 
construction project in New York.

SOUTH CAROLINA
Industrial Flooring and Hardstand Areas

A key target market for EdenCrete®is industrial flooring for 
manufacturing / warehouse flooring, and hard stand areas. 
Interest for similar applications, in the range of performance 
benefits and project lifecycle cost savings delivered by 
EdenCrete®, continues to grow amongst a range of general 
contractors, architects, engineers, and ready-mix suppliers.

During the year, the first order was received for EdenCrete® 
for use in a concrete storage area at a plant in South 
Carolina for a major international tyre company. Following 
the successful results delivered by EdenCrete®, Eden US 
received its largest, repeat order (not related to a GDOT 
project), to supply US$120,000 worth of EdenCrete® to the 
same contractor who had previously used EdenCrete® this 

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEwas due to no prior applications having been made to import 
into Australia products containing carbon nanotubes.

After extensive communications over many months, NICNAS, 
the Australian Government body that assesses chemical 
products that are proposed to be manufactured in, or 
imported into, Australia advised that it considers that it has 
received sufficient information to enable it to commence 
the formal assessment of the EdenCrete® products that 
Parchem, wishes to import.

Commercial trials of EdenCrete®, which is being paid for 
by the customers, have since commenced and Parchem 
has already received approximately 40 requests to conduct 
commercial trials. It is hoped that the final approval that 
will enable unrestricted commercial sales in Australia to 
commence, will be received later in 2020. 

Figure 16. Warehouse floor project for second large company in 
South Carolina.

UTAH

INDIA 

During the year two ready-mix plants and one shotcrete 
operator installed storage and dispensing equipment to add 
EdenCrete® in their standard concrete mixes.

ILLINOIS, INDIANA, MASSACHUSETTS, NORTH 
CAROLINA, WISCONSIN, OKLAHOMA, FLORIDA, 
TEXAS, PENNSYLVANIA

During the year, trials with new and a number of potentially 
significant customers that operate in a range of market 
sectors took place, are presently underway or being planned 
in Illinois, Indiana, Massachusetts, North Carolina, Wisconsin, 
Oklahoma, Florida, Texas and Pennsylvania. 

This significant extension of the EdenCrete® footprint in 
the US is an important development and is considered 
likely to result in significantly increased US sales emerging 
over the coming year. The recent appointment of the initial 
commission-only sales representatives, who operate in 
States where EdenCrete® products have not yet been 
sold, is anticipated to accelerate this growth in the US 
EdenCrete® footprint.

Further, based upon Eden’s experience over the past three 
years a considerable proportion of the growth in EdenCrete® 
sales occur following successful trials or projects, with news 
of successes being passed on to potential new customers 
by various means, including by contractors who undertook 
the successful project. 

AUSTRALIA AND NEW ZEALAND EXCLUSIVE 
DISTRIBUTOR 

In November 2019, Parchem Construction Supplies Pty Ltd 
(Parchem), the Australian and New Zealand distributor of the 
EdenCrete® range of products, was successful in obtaining 
approval in Australia for up to 60,000 litres of EdenCrete® to 
be imported and trialled. The delay in obtaining this approval 

During the year a series of meetings took place in India 
with a number of major concrete manufacturers and/
or construction companies, as well as with a number of 
relevant government agencies. A very positive response was 
received from all groups. 

As a result, a number of samples of Indian cement and fly 
ash were dispatched to Eden in Colorado for preliminary 
trialling, which produced positive results. In consequence 
Eden’s chief scientist visited India a number of times and 
participated in laboratory trials that were conducted by a 
number of these large Indian companies. 

Eden has, since the end of the financial year, received its 
first purchase order to be used for commercial applications 
in India, from Godrej Ready Mix, a part of the highly 
respected Godrej Group of companies, with which Eden has 
been developing a range of EdenCretePz® concrete mixes 
with high fly ash content for some time.

EUROPE

Extensive trials of EdenCrete® products by a large European 
construction company commenced in July 2019 and were 
scheduled to be completed in the first half of 2020. However 
due to COVID 19, the trials were shut down from February 
2020 until August 2020.At the date of this report these trials 
have recommenced, with finalisation anticipated before the 
end of CY2020.

ISRAEL

A diversified Israeli company, that runs several ready-mix 
plants has been undertaking repeated trials of EdenCrete® 
products for a range of applications and is achieving 
encouraging results. Subsequent to the end of the year 
the Israeli company placed its first order of EdenCrete® 
products that are to be used in a number of commercial 
trials.

11

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEREVIEW OF OPERATIONS (Continued)

SOUTH KOREA

Trials of EdenCrete® by a number of South Korean 
companies have taken place in spite of difficulties due to 
COVID 19. One such trial with a major ready-mix company is 
still ongoing. 

OPTIBLEND®

During the year Eden recorded the following Optiblend® 
sales:

Optiblend® Invoiced Sales for the  
year ended 30 June 2020

USA

INDIA

TOTAL

SALES (A$000’s)

759

170

929

These sales represent a 29% increase over the aggregate 
sales recorded in FY2019, and Eden remains optimistic that 
OptiBlend® sales will continue to increase over the coming 
year in both the USA and India. The proposed appointment 
of further suitable, commission-only sales representatives 
could assist in achieving this outcome.

EDENPLASTTM

A Japanese plastics company has expressed an interest 
in testing EdenPlast® and a concentrated master match 
for testing by the Japanese company is presently being 
made in Australia. A non-disclosure agreement to protect 
each party’s intellectual property rights is currently being 
finalized.

INTELLECTUAL PROPERTY

USA Patents Allowed for EdenCrete® and EdenPlast®

During the year, the US Patent and Trademark Office issued 
one application and allowed another application, both were 
lodged in 2017. Details of these two USA patents are as 
follows:

•  US Patent application no. 15/597,198 has been allowed 
and includes 24 claims directed to the production of the 
EdenCrete® family of products; and

•  US Patent No. 10,472,240 has issued and includes 16 
claims directed to the production of the EdenPlast® 
family of products.

In addition, corresponding patent applications have been 
lodged in the USA that include claims directed to the 
composition of the EdenCrete® and EdenPlast® family of 
products. Corresponding patent applications have also 
been lodged in five other countries pursuant to the Patent 
Convention Treaty.

These two USA patents are both broad in their scope, 
covering in each case the use of a wide variety of carbon 
nanoparticles in the manufacture of concrete and plastic 
products including carbon nanotube particles, carbon 
nanofiber particles, graphene particles, graphite particles, 
carbon black, polycrystalline carbon particles, nano-
diamonds and fullerene particles.

The two USA patents are intended to provide significant 
protection in the USA for the considerable intellectual 
property that Eden has developed over the past 10 years 
in relation to the EdenCrete® and EdenPlast® family of 
products.

Eden now holds ten USA patents protecting its technologies 
in different areas, along with corresponding patents 
in a number of other countries. Eden also holds three 
other current USA patent applications that are still being 
considered.

CORPORATE
FY 2020 Share Purchase Plan 

During the year, the company completed a successful share 
purchase plan (SPP), which raised $2,908,000 (before 
costs) through the issue of 58,160,000 shares at an issue 
price of 5 cents per share. The funds raised were used for 
general working capital.

New Executive Appointments

During the year Dag Grantham took over the role of CEO of 
Eden US. Dag joined Eden in September 2016 as Senior Vice 
President Business Development.  Dag has an impressive 
background that includes 20 years of distinguished 
leadership in the US Air Force, General Manager of National 
Specialty Aggregates, a wholly owned subsidiary of Pebble 
Technology Inc., and Director of Flight Standards for NetJets 
Aviation. 

Secured loan of US $3 million completed 

To fund ongoing working capital, Eden secured US$3.00 
million (A$4,086,437) in debt financing by way of an 
18-months, interest only loan which is secured against 
Eden’s three freehold properties in the USA.

Cares Act Loan

Eden US also received a USA Government backed loan of 
US$634,000, under the US Government’s COVID 19 stimulus 
package, which is likely to become a grant and not be 
repayable provided certain conditions related to continued 
employment are met.

FY2021 Share Purchase Plan 

Since the end of FY2020, Eden completed a further, well 
supported Share Purchase Plan (SPP) that closed on 23 July 
2020, with shareholders subscribing a total of $4,244,897 
for 151,603,497 shares. 

12

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEDIRECTORS’ REPORT

Your directors present their report on the Company and 
its controlled entities (the Group) for the financial year 
ended 30 June 2020.

assets less current liabilities, has decreased from 
$2,853,033 at 30 June 2019 to $709,646 at 30 June 
2020.

Directors
The names of directors in office at any time during or 
since the end of the year are:

Significant Changes in State of Affairs
There have been no significant changes in the state of 
affairs that occurred during the financial year.

Gregory H Solomon 

Stephen D Dunmead

Douglas H Solomon 

Lazaros Nikeas

Directors have been in office since the start of the 
financial year to the date of this report.

Company Secretary 
The following person held the position of company 
secretary during and at the end of the financial year:

Mr Aaron P Gates has worked for Eden Innovations Ltd 
for the past 12 years.  He is a Chartered Accountant and 
Chartered Secretary.  He has completed a Bachelor of 
Commerce (Curtin University) with majors in accounting 
and business law and completed a Diploma of Corporate 
Governance.  Prior to joining Eden he worked in public 
practice in audit and corporate finance roles.

Principal Activities
Eden Innovations Ltd produces and sells a high 
performance concrete admixture, EdenCrete® and retrofit 
dual fuel technology, OptiBlend®, developed for diesel 
generator sets.

There were no significant changes in the nature of the 
consolidated group’s principal activities during the 
financial year.

Operating Results
The consolidated loss of the Group after providing for 
income tax amounted to $9,105,991 (2019: $9,216,320).

Dividends Paid or Recommended
No dividends were paid or declared for payment during the 
year.

Review of Operations
A review of the operations of the Group during the year 
ended 30 June 2020 is set out in the Review of Operations 
on Page 5.

Financial Position
The net assets of the consolidated group have decreased 
from $21,039,734 at 30 June 2019 to $15,732,512 at 
30 June 2020. The group’s working capital, being current 

After Balance Date Events
The impact of the Coronavirus (COVID-19) pandemic is 
ongoing and whilst it has had limited financial impact 
for the Group up to 30 June 2020, it is not practicable to 
estimate the potential impact, positive or negative, after 
the reporting date. The situation is rapidly developing and 
is dependent on measures imposed by the Australian 
Government and other countries, such as maintaining 
social distancing requirements, quarantine, travel 
restrictions and any economic stimulus that may be 
provided.

On 28 July 2020 151,603,497 fully paid ordinary shares 
were issued at $0.028 each pursuant to a Share Purchase 
Plan, raising $4,244,897.

On 30 July 2020 2,206,896 fully paid ordinary shares were 
issued to Mr Stephen Dunmead and Mr Lazaros Nikeas 
pursuant to resolutions passed at the general meeting 
held on 2 July 2019.

No other matters or circumstances have arisen since the 
end of the financial year which significantly affected or 
may significantly affect the operations of the Group, the 
results of those operations, or the state of affairs of the 
Group in future financial years.

Future Developments, Prospects and Business 
Strategies
The Group proposes to continue developing and marketing 
its technologies, including EdenCrete® and OptiBlend® as 
detailed in the Review of Operations.

Environmental Issues
The Group is subject to environmental regulation and 
complies fully with all requirements.

13

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEDIRECTORS’ REPORT

Information on Directors
Gregory H Solomon 
Qualifications 

Experience 

Executive Chairman

LLB
Appointed Executive Chairman in 2004.  A qualified lawyer with more than 30 years’ Australian 
and international experience in a wide range of areas including commercial negotiation and 
corporate law. Following 15 years’ experience as a director on a number of ASX listed companies, 
for the past 15 years in his role as Executive Chairman he has been responsible for initiating and 
managing the entire business development of all companies in the Group since its incorporation.

Interest in Shares and Options 

45,369,342 Ordinary Shares 

2,037,244 EDEOB Options

Directorships held in other listed  

Tasman Resources Limited (ASX:TAS) 

entities 

Conico Limited (ASX:CNJ)

Douglas H Solomon 
Qualifications 

Experience 

Non-Executive Director

BJuris LLB (Hons)
Board member since May 2004. A Barrister and Solicitor with more than 30 years’ experience 
in the areas of mining, corporate, commercial and property law. He is a partner in the legal firm, 
Solomon Brothers.

Interest in Shares and Options 

38,945,878 Ordinary Shares 

1,756,633 EDEOB Options

Directorships held in other listed  

Tasman Resources Limited (ASX:TAS)

entities 

Conico Limited (ASX:CNJ)

Lazaros Nikeas 
Qualifications 

Experience 

Non-Executive Director

B.A. 
Board member since May 2018. Mr Nikeas is an experienced investment and private equity 
professional with over 17 years of US finance experience. Mr Nikeas is currently a Principal 
investment manager for Weston Energy LLC, a portfolio company of New York private equity 
group, Yorktown Partners LLC. Prior to this, he was Lead Partner and Principal of Traxys Capital 
Partners, a private equity vehicle focused on mining, chemicals and industrial investments in 
partnership with The Carlyle Group. 

Before moving into private equity, he served as the Head of Corporate Finance Advisory for 
Materials, Mining and Chemicals for North America for BNP Paribas for five years. Other 
investment banking roles included Partner in Mergers & Acquisitions Advisory at Hill Street 
Capital for eight years and as a Corporate Finance Analyst at Morgan Stanley, where he began 
his career. Altogether, he has advised on over US$25 billion of mergers and acquisitions 
transactions. 

Interest in Shares and Options 

2,920,760 Ordinary Shares

Directorships held in other listed entities  -

Stephen D Dunmead 
Qualifications 

Experience 

Non-Executive Director

B.Sc., M.Sc., Ph.D.
Board member since May 2018. Based in the US, Dr Dunmead is a global business executive 
with over 30 years of strong operational leadership experience in the US based global materials 
industry. He served as Chief Operating Officer at SWM International (NYSE: SWM) in Georgia 
where he was responsible for over 3,000 employees across 20 sites of the company’s global 
operations in North and South America, Europe and Asia, accounting for US$0.8 billion of revenue 
and US$180 million in EBITDA. At SWM International he led the business into the high growth and 
high margin filtration and medical sectors. 

Prior to SWM International, Dr Dunmead spent over 15 years at OM Group (NYSE: OMG) in 
Ohio where he was a member of the Corporate Executive Team and had responsibility for six 
businesses with more than 6,500 employees across 32 sites in North America, Europe, Asia and 
Africa. Together, these businesses represented US$1.5 billion in revenue and US$255 million in 
EBITDA. Dr Dunmead holds 25 US Patents on Advanced Materials and Specialty Chemicals.

Interest in Shares and Options 

3,920,760 Ordinary Shares

Directorships held in other listed entities  -

14

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
 
 
 
 
 
DIRECTORS’ REPORT

REMUNERATION REPORT (AUDITED)
This report details the nature and amount of remuneration 
for each director of Eden Innovations Ltd, and for the 
executives receiving the highest remuneration.

Remuneration policy
The remuneration policy of Eden Innovations Ltd has been 
designed to align director and executive objectives with 
shareholder and business objectives by providing a fixed 
remuneration component and offering specific long-term 
incentives based on key performance areas affecting the 
consolidated Group’s financial results. The board of Eden 
Innovations Ltd believes the remuneration policy to be 
appropriate and effective in its ability to attract and retain 
the best executives and directors to run and manage the 
consolidated Group, as well as create goal congruence 
between directors, executives and shareholders.
The board’s policy for determining the nature and amount 
of remuneration for board members and senior executives 
of the economic entity is as follows:
¬  Executives receive a base salary (which is based on 
factors such as length of service and experience), 
superannuation (401k match), fringe benefits and share 
performance rights.

Executives are also entitled to participate in the employee 
share and option arrangements.
All remuneration paid to directors and executives is valued 
at the cost to the Company and expensed. Options are 
valued using the Black-Scholes methodology.  The Group 
does not have a policy on directors hedging their shares.
The maximum aggregate amount of fees that can be 
paid to non-executive directors is subject to approval 
by shareholders at the Annual General Meeting. Fees for 
non-executive directors are not linked to the performance 
of the consolidated Group. However, to align directors’ 
interests with shareholder interests, the directors are 
encouraged to hold shares in the Company and are able to 
participate in the employee share option plan.

Performance-based remuneration
No performance based remuneration was paid during the 
year.

Key Management Personnel Remuneration Policy
The Board's policy for determining the nature and amount 
of remuneration of management for the Group is as 
follows:
The remuneration structure for key management 
personnel is based on a number of factors, including 
length of service, particular experience of the individual 
concerned, and overall performance of the Company. 
The contracts for service between the Company and 
key management personnel are on a continuing basis, 
the terms of which are not expected to change in the 
immediate future. Upon retirement key management 
personnel are paid employee benefit entitlements accrued 
to date of retirement. Any ESOP options not exercised 
before or on the date of termination lapse.

Names and positions held of economic and parent entity 
key management personnel in office at any time during 
the financial year are:
Gregory H Solomon 
- Executive Chairman
Douglas H Solomon 
- Non-Executive Director
Lazaros Nikeas 
- Non-Executive Director 
Stephen D Dunmead 
- Non-Executive Director 
Don Grantham Jr 
- President & CEO - Eden Innovations LLC  
  (formerly Senior Vice President Business Development –  
  Eden Innovations LLC)
Roger W Marmaro 
- President Sales Eden Innovations LLC  
  (formerly President Eden Innovations LLC)
Aaron P Gates 
- Company Secretary / Chief Financial Officer

15

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
DIRECTORS’ REPORT

Key Management 
Person

Short-term Benefits

Post- 
Employment
Benefits

Other  
Long Term  
Benefits

Termination 
Benefits

Share- based  
Payments

Total

Salary and 
Fees

Non-cash
benefit

Other

Super- 
annuation

Other

Other

Equity

Options

Performance 
Rights

$

$

$

$

$

$

$

$

$

$

2020

Gregory Solomon

281,250

Douglas Solomon

Lazaros Nikeas

50,625

50,625

Stephen Dunmead(a)

176,197

Don Grantham Jr (c)

400,112

Roger Marmaro(d) 

499,305

Aaron Gates

(b)

-

-

-

-

22,306

26,272

-

1,458,114

48,578

2019

Gregory Solomon

Douglas Solomon

Lazaros Nikeas

300,000

54,000

54,000

Stephen Dunmead(a)

267,256

-

-

-

-

Roger Marmaro(d) 

586,906

32,830

Aaron Gates

(b)

-

1,262,162

32,830

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,125

1,283

-

-

23,782

19,921

-

52,111

28,500

5,130

-

-

25,188

-

58,818

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32,000

32,000

-

-

-

-

-

-

-

-

288,375

51,908

82,625

208,197

-

-

-

27,423

62,968

33,536

507,159

43,610

652,076

944

17,222

18,166

64,000

91,335

94,368 1,808,506

-

-

48,000

88,000

-

-

-

-

-

-

116,410

5,873

-

-

-

-

-

-

328,500

59,130

102,000

355,256

761,334

5,873

136,000

122,283

- 1,612,093

(a)  Mr Stephen Dunmead provided short-term consulting 

(d)  The appointment of Roger Marmaro may be 

terminated by giving not less than two months’ 
written notice.

Other transactions with key management personnel
Management fees of $262,500 were paid and $18,750 
was payable to Princebrook Pty Ltd, a company in which 
Mr GH Solomon and Mr DH Solomon have an interest. 

Legal fees of $23,581, based on normal market rates, 
were paid to Solomon Brothers, a firm in which Mr GH 
Solomon and Mr DH Solomon are partners.

services to the group during the period.

(b)  This officer is provided by Princebrook Pty Ltd (a 
company in which Mr Gregory Solomon and Mr 
Douglas Solomon have an interest) under the 
Management Services Agreement with the Company. 
The Management Services Agreement may be 
terminated by giving not less than three months’ 
written notice. During the year the Company paid 
$281,250 (2019: $300,000) to Princebrook Pty Ltd 
for management services. It was agreed that the 
Management Services fee was reduced by 25% for the 
months of April to June 2020.

(c)  The appointment of Don Grantham Jr may be 

terminated by giving not less than three months’ 
written notice. Don Grantham Jr. was appointed as 
President & CEO - Eden Innovations LLC during the 
year, this table includes all remuneration paid during 
the year to Don Grantham Jr.

16

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEDIRECTORS’ REPORT

Number of Options Held by Key Management Personnel

Balance 
30.6.2019

Granted as 
Compensation

Options  
Exercised

Net Change* 
Other

Balance 
30.6.2020

Total Vested 
30.6.2020

Total 
Exercisable 
30.6.2020

Total Unex-
ercisable 
30.6.2020

Gregory Solomon

2,037,244

Douglas Solomon

1,756,633

Lazaros Nikeas

2,400,000

Stephen Dunmead

2,400,000

-

-

-

-

Don Grantham Jr

-

1,000,000

Roger Marmaro

10,000,000

Aaron Gates

458,750

-

-

Total

19,052,627

1,000,000

-

-

-

-

-

-

-

-

-

-

2,037,244

2,037,244

2,037,244

1,756,633

1,756,633

1,756,633

(2,400,000)

(2,400,000)

-

-

-

-

-

-

-

1,000,000

1,000,000

1,000,000

(10,000,000)

(450,000)

-

8,750

-

8,750

-

8,750

(15,250,000)

4,802,627

4,802,627

4,802,627

-

-

-

-

-

-

-

-

* Net Change Other refers to options that have been purchased, sold, lapsed or issued during the year.

Number of Performance Rights held by Key Management Personnel

Balance 30.6.2019

Received as  
Compensation

Exercised

Balance 30.6.2020

Gregory Solomon

Douglas Solomon

Lazaros Nikeas

Stephen Dunmead

Don Grantham Jr

Roger Marmaro

Aaron Gates

Total

-

-

-

-

-

-

-

-

-

-

-

-

3,000,000

3,500,001

1,200,000

7,700,001

-

-

-

-

-

-

-

-

-

-

-

-

3,000,000

3,500,001

1,200,000

7,700,001

Number of Shares held by Key Management Personnel

Balance 30.6.2019

Received as  
Compensation

Options Exercised

Net Change* Other

Balance 30.6.2020

Gregory Solomon

Douglas Solomon

Lazaros Nikeas

Stephen Dunmead

Don Grantham Jr

Roger Marmaro

Aaron Gates

Total

44,819,342

38,645,878

-

-

-

2,478,648

192,500

86,136,368

-

-

1,817,312

2,817,312

-

-

-

4,634,624

-

-

-

-

-

-

-

-

550,000

300,000

-

-

-

-

-

850,000

45,369,342

38,945,878

1,817,312

2,817,312

-

2,478,648

192,500

91,620,992

* Net Change Other refers to shares purchased or sold during the financial year.



17

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEDIRECTORS’ REPORT

Meetings of Directors

During the financial year, 8 meetings of directors were held. Attendances by each director during the year were as follows:

Number eligible to attend

Number attended

Gregory H Solomon

Douglas H Solomon

Lazaros Nikeas

Stephen D Dunmead

8

8

8

8

8

8

8

8

Unissued shares under options

At the date of this report, the unissued ordinary shares of Eden Innovations Ltd under option are as follows:

Issue Date

28 August 2017

8 March 2019

20 June 2019

20 June 2019

20 December 2019

Date of Expiry

Exercise Price Number under Option

30 November 2020

8 March 2021

1 June 2021

1 June 2021

19 December 2022

$0.25

$0.08

$0.07

$0.08

$0.065

330,000

69,695,884

6,000,000

6,000,000

1,000,000

83,025,884

The Options expiring on 30 November 2020 and 19 December 
2022 are all held, pursuant to the Company’s Employee 
Share Option Plan, by overseas employees or directors of 
subsidiaries of the Company or key consultants. No person 
entitled to exercise the option has any right by virtue of the 
option to participate in any share issue of any other body 
corporate.

At the date of this report unissued shares of the Group under 
performance rights are  26,391,012.

Indemnifying Officers 

The Company has arranged for an insurance policy to insure 
the directors against liabilities for costs and expenses 
incurred by them in defending any legal proceedings arising 
out of their conduct while acting in the capacity of director of 
the Company, other than conduct involving a wilful breach of 
duty in relation to the Company. The total premium payable 
was approximately $116,050.

Auditor’s Independence Declaration

The lead auditor’s independence declaration for the year 
ended 30 June 2020 has been received and can be found on 
page 19.

Rounding of amounts

Eden Innovations Ltd is a type of Company referred to in 
ASIC Corporations (Rounding in Financial/Directors’ Reports) 
Instrument 2016/191 and therefore the amounts contained 
in this report and in the financial report have been rounded to 
the nearest $1.

Signed in accordance with a resolution of the Board of 
Directors.

Proceedings on Behalf of Company

____________________________________________________

Gregory H Solomon

Executive Chairman

Dated this 23rd day of September 2020

No person has applied for leave of Court to bring proceedings 
on behalf of the Company or intervene in any proceedings 
to which the Company is a party for the purpose of taking 
responsibility on behalf of the Company for all or any part of 
those proceedings.

The Company was not a party to any such proceedings during 
the year.

Non-audit Services

No fees for non-audit services were paid or are payable to the 
external auditors during the year ended 30 June 2020.

18

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDELead auditor’s independence declaration under section 307C of the 
Corporations Act 2001 

To the directors of Eden Innovations Ltd  

I declare that, to the best of my knowledge and belief, in relation to the audit for the financial 
year ended 30 June 2020 there have been: 

(i)  no  contraventions  of  the  auditor’s  independence  requirements  as  set  out  in  the 

Corporations Act 2001 in relation to the audit; and 

(ii)  no  contraventions  of  any  applicable  code  of  professional  conduct  in  relation  to  the 

audit. 

Nexia Perth Audit Services Pty Ltd 

M. Janse Van Nieuwenhuizen|Director 
Perth 
23 September 2020 

19

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
 
 
 
 
 
 
 
 
 
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER 
COMPREHENSIVE INCOME FOR YEAR ENDED 30 JUNE 2020

Revenue

Other income

Changes in inventories

Raw materials and consumables used

Depreciation and amortisation expense

Employee benefits expense

Finance costs

Legal and consultants

Management fees

Other financial items

Other expenses

Travel and accommodation

Loss before income tax

Income tax (expense)/benefit

Loss for the year

Other Comprehensive Income / (Loss)

Items that may be reclassified subsequently to profit or loss

Foreign currency translation reserve

Income tax relating to comprehensive income

Total Other Comprehensive Income / (Loss), net of tax

Total Comprehensive Income / (Loss) attributable to 
members of the parent

Note

Consolidated Group

2020 
$

2019 
$

2

2,427,105

2,334,901

4,034

(54,646)

(504,926)

28,046

82,586

(489,447)

(1,290,148)

(1,089,362)

3a

(5,482,160)

(5,526,330)

4

7

(477,371)

(34,167)

(948,088)

(1,321,719)

(281,250)

(300,000)

19,409

(8,893)

(2,199,101)

(2,477,458)

(346,640)

(488,164)

(9,133,782)

(9,290,007)

27,791

73,687

(9,105,991)

(9,216,320)

482,298

622,754

-

-

482,298

622,754

(8,623,693)

(8,593,566)

Basic/Diluted loss per share (cents per share)

6

(0.5316)

(0.5969)

The accompanying notes form part of these financial statements.

20

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDECONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2020

ASSETS

CURRENT ASSETS

Cash and cash equivalents

Trade and other receivables

Inventories

Other current assets

TOTAL CURRENT ASSETS

NON-CURRENT ASSETS

Property, plant and equipment

Intangible assets

TOTAL NON-CURRENT ASSETS

TOTAL ASSETS

CURRENT LIABILITIES

Trade and other payables

Interest bearing liabilities

Provisions

TOTAL CURRENT LIABILITIES

NON-CURRENT LIABILITIES

Interest bearing liabilities

Other liabilities

TOTAL NON-CURRENT LIABILITIES

TOTAL LIABILITIES

NET ASSETS

EQUITY

Issued capital

Reserves

Accumulated losses

TOTAL EQUITY

The accompanying notes form part of these financial statements.

Note

Consolidated Group

2020 
$

2019 
$

9

10

11

12

13

14

15

14

16

20

1,388,683

3,217,555

396,366

701,781

98,084

315,267

735,290

58,307

2,584,914

4,326,419

11,999,422

12,463,621

8,223,113

6,524,192

20,222,535

18,987,813

22,807,449

23,314,232

878,389

816,566

180,313

1,069,010

247,422

156,954

1,875,268

1,473,386

5,181,439

18,230

5,199,669

7,074,937

772,355

28,757

801,112

2,274,498

15,732,512

21,039,734

105,503,776

102,636,700

9,885,426

8,953,733

(99,656,690)

(90,550,699)

15,732,512

21,039,734

21

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR  
YEAR ENDED 30 JUNE 2020

Consolidated Group

Fully Paid 
Ordinary 
Shares

Share based 
payment 
Reserve

Foreign 
Currency 
Translation 
Reserve 

Accumulated 
Losses

Total

$

$

$

$

$

Balance at 30 June 2018

91,230,956

7,668,777

196,216 (81,334,379)

17,761,570

Shares issued during the year, net of issue costs

11,405,744

Share based payments during the year

Loss for year

Other comprehensive income

Total comprehensive income/(loss)

-

-

-

-

-

465,986

-

-

-

-

-

-

622,754

622,754

-

-

11,405,744

465,986

(9,216,320)

(9,216,320)

-

622,754

(9,216,320)

(8,593,566)

Balance at 30 June 2019

102,636,700

8,134,763

818,970 (90,550,699)

21,039,734

Shares issued during the year, net of issue costs

2,867,076

Share based payments during the year

Loss for year

Other comprehensive income

Total comprehensive income/(loss)

-

-

-

-

-

449,395

-

-

-

-

-

-

482,298

482,298

-

-

2,867,076

449,395

(9,105,991)

(9,105,991)

-

482,298

(9,105,991)

(8,623,693)

Balance at 30 June 2020

105,503,776

8,584,158

1,301,268 (99,656,690)

15,732,512

The accompanying notes form part of these financial statements.

22

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
CONSOLIDATED STATEMENT OF CASH FLOWS FOR YEAR ENDED 30 JUNE 2020

CASH FLOWS FROM OPERATING ACTIVITIES

Receipts from customers

Payments to suppliers and employees

Income taxes (paid)/received

Interest paid

Interest received

Net cash used in operating activities

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of property, plant and equipment

Payment for research and development

Net cash used in investing activities

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from issue of shares, net of issue costs

Proceeds from borrowings, net of borrowing costs

Repayment of borrowings

Net cash provided by financing activities

Net increase/(decrease) in cash held

Net increase/(decrease) due to foreign exchange movements

Cash at beginning of financial year 

Cash at end of financial year

The accompanying notes form part of these financial statements.

Note

Consolidated Group

2020 
$

2019 
$

2,441,797

2,400,657

(9,729,590)

(9,623,820)

27,791

(119,376)

3,688

73,687

(27,677)

3,167

(7,375,690)

(7,173,986)

(97,120)

(1,980,308)

(2,180,633)

(2,068,407)

(2,277,753)

(4,048,715)

2,843,473

8,125,557

11,298,297

-

(3,122,254)

(355,086)

7,846,776

10,943,211

(1,806,667)

(279,490)

(22,205)

3,217,555

1,388,683

7,315

3,489,730

3,217,555

18

11

12

9

23

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING 
POLICIES
The financial report is a general purpose financial 
report that has been prepared in accordance with 
Australian Accounting Standards, other authoritative 
pronouncements of the Australian Accounting Standards 
Board and the Corporations Act 2001. The financial 
report complies with all International Financial Reporting 
Standards (IFRS) issued by the International Accounting 
Standards Board in their entirety.

The financial report covers the consolidated Group of 
Eden Innovations Ltd and its controlled entities as at and 
for the year ended 30 June 2020. Eden Innovations Ltd 
is a listed public company, incorporated and domiciled in 
Australia. The Group is a for-profit entity and primarily is 
involved in clean technology solutions.

The financial report was authorised for issue on 23 
September 2020 by the Board of Directors.

The following is a summary of the material accounting 
policies adopted by the consolidated Group in the 
preparation of the financial report. The accounting policies 
have been consistently applied, unless otherwise stated.

Basis of Preparation

The accounting policies set out below have been 
consistently applied to all years presented. 

Reporting Basis and Conventions

The financial report has been prepared on an accruals 
basis and is based on historical costs modified by the 
revaluation of selected non-current assets, financial 
assets and financial liabilities for which the fair value 
basis of accounting has been applied. These consolidated 
financial statements are presented in Australian dollars, 
which is the parent’s functional currency. The subsidiaries’ 
functional currencies are USD and INR.

Going Concern

These financial statements have been prepared on a 
going concern basis, which contemplates continuity of 
normal business activities and the realisation of assets 
and extinguishment of liabilities in the ordinary course of 
business.

The Group has reported a net loss for the year of 
$9,105,991 (2019: $9,216,320) and a cash outflow from 
operating activities of $7,375,690 (2019: $7,173,986). The 
directors are confident that the Group, subject to being 
able to raise further capital or debt funding, will be able 
to continue its operations as a going concern. Without 
such capital and or funding, the net loss for the year 
and the cash outflow from operating activities indicate 
the existence of a material uncertainty which may cast 
significant doubt about the Group’s ability to continue as a 
going concern. 

The continuing applicability of the going concern basis 
of accounting is dependent upon the Group’s ability to 
source additional finance. Unless additional finance is 
received the Group may need to realise assets and settle 
liabilities other than in the normal course of business and 
at amounts which could differ from the amounts at which 
they are stated in these financial statements.

Accounting Policies

a. Principles of Consolidation

  A controlled entity is any entity Eden Innovations Ltd is 
exposed to, or has rights to, variable returns from its 
involvement with the entity and has the ability to affect 
those returns through its power to direct the activities 
of the entity.  A list of controlled entities is contained 
in Note 21 to the financial statements. All controlled 
entities have a June year-end.

  All inter-company balances and transactions between 

entities in the consolidated group, including any 
unrealised profits or losses, have been eliminated on 
consolidation. Accounting policies of subsidiaries have 
been changed where necessary to ensure consistencies 
with those policies applied by the parent entity.

b. Income Tax

  The charge for current income tax expense is based on 
the profit for the year adjusted for any non-assessable 
or disallowed items. It is calculated using the tax rates 
that have been enacted or are substantially enacted by 
the balance sheet date.

  Deferred tax is accounted for using the balance sheet 
liability method in respect of temporary differences 
arising between the tax bases of assets and liabilities 
and their carrying amounts in the financial statements. 
No deferred income tax will be recognised from the 
initial recognition of an asset or liability, excluding 
a business combination, where there is no effect on 
accounting or taxable profit or loss. Deferred income tax 
assets are recognised to the extent that it is probable 
that future tax profits will be available against which 
deductible temporary differences can be utilised.

  Eden Innovations Ltd, Eden Innovations Holdings Pty 

Ltd and Eden Energy Holdings Pty Ltd, its wholly-owned 
Australian subsidiaries, have formed an income tax 
consolidated group under the tax consolidation regime. 
The Group notified the Australian Tax Office that it had 
formed an income tax consolidated group to apply from 
1 July 2005. The tax consolidated group has entered 
a tax sharing agreement whereby each company in 
the group contributes to the income tax payable in 
proportion to their contribution to the net profit before 
tax of the tax consolidated group. The R&D tax rebate is 
recognised as income tax benefit upon receipt.

24

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

c. Inventories

The depreciation rates used for each class of depreciable 

Inventories are measured at the lower of cost and net 
realisable value. The cost of manufactured products 
includes direct materials, direct labour and an 
appropriate portion of variable and fixed overheads. 
Costs are assigned on the basis of first-in, first-out.  

d. Segment reporting

  Segment results that are reported to the Group’s board 
of directors (the chief operating decision maker) include 
items directly attributable to a segment as well as those 
that can be allocated on a reasonable basis.

e. Employee Benefits

  Provision is made for the Company’s liability for 

employee benefits arising from services rendered by 
employees to balance date. Employee benefits that 
are expected to be settled within one year have been 
measured at the amounts expected to be paid when the 
liability is settled, plus related on-costs. 

f. Revenue

  Revenue is recognised when or as the Group transfers 
control of products or provides services to a customer 
at the amount to which the Group expects to be 
entitled as the performance obligation is met. If the 
consideration includes a variable component, the 
expected consideration is adjusted for the estimated 
impact of the variable component at the point of 
recognition and re-estimated at every reporting period. 
Interest revenue is recognised on a proportional basis 
taking into account the interest rates applicable to the 
financial assets.

g. Property, Plant and Equipment 

  Each class of property, plant and equipment is carried 

at cost less, where applicable, any accumulated 
depreciation and impairment losses.

  Property, plant and equipment are initially recognised 

at acquisition cost or manufacturing cost, including any 
costs directly attributable to bringing the assets to the 
location and condition necessary for it to be capable 
of operating in the manner intended by the Group’s 
management.

  The carrying amount of property, plant and equipment 
is reviewed annually by directors to ensure it is not 
in excess of the recoverable amount of these assets. 
The recoverable amount is assessed on the basis of 
the expected net cash flows that will be received from 
the asset’s employment and subsequent disposal. The 
expected net cash flows have been discounted to their 
present values in determining recoverable amounts.

assets are:

Class of Fixed Asset

Depreciation Rate

Plant and equipment

6 – 20% straight line

Buildings

Land

4% straight line

Nil

  Gains and losses on disposals are determined by 

comparing proceeds with the carrying amount. These 
gains and losses are included in the statement of profit 
or loss and other comprehensive income. When revalued 
assets are sold, amounts included in the revaluation 
reserve relating to that asset are transferred to retained 
earnings.

h. Financial Instruments

Initial recognition and measurement

  Financial assets and financial liabilities are recognised 
when the entity becomes a party to the contractual 
provisions of the financial instrument. Financial 
assets are initially measured at fair value adjusted for 
transaction costs.

  Classification and subsequent measurement 

  For the purpose of subsequent measurement, financial 

assets are classified into the following categories:

•  amortised cost

•  fair value through profit or loss (FVTPL)

•  equity instruments at fair value through other 

comprehensive income (FVOCI)

•  debt instruments at fair value through other 

comprehensive income (FVOCI).

  All income and expenses relating to financial assets 

that are recognised in profit or loss are presented within 
finance costs, finance income or other financial items. 
The classification is determined by both the entity’s 
business model for managing the financial asset and 
the contractual cash flow characteristics of the financial 
asset.

  Financial assets are measured at amortised cost if 

the assets meet the following conditions (and are not 
designated as FVTPL):

•  they are held within a business model whose objective 
is to hold the financial assets to collect its contractual 
cash flows

•  the contractual terms of the financial assets give rise 
to cash flows that are solely payments of principal and 
interest on the principal amount outstanding.

25

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

  After initial recognition, these are measured at amortised 
cost using the effective interest method. Discounting is 
omitted where the effect of discounting is immaterial. 
The entity’s cash and cash equivalents, trade and most 
other receivables fall into this category of financial 
instruments.

  Trade and other receivables 

  The entity makes use of a simplified approach in 

accounting for trade and other receivables and records 
the loss allowance as lifetime expected credit losses. 
These are the expected shortfalls in contractual cash 
flows, considering the potential for default at any point 
during the life of the financial instrument. In calculating, 
the entity uses its historical experience, external 
indicators and forward-looking information to calculate 
the expected credit losses.

  Classification and measurement of financial liabilities 

and intangible assets with indefinite lives. 

  Where it is not possible to estimate the recoverable 
amount of an individual asset, the Group estimates 
the recoverable amount of the cash-generating unit to 
which the asset belongs.

j.  Intangibles

  Research and development 

  Expenditure during the research phase of a project is 

recognised as an expense when incurred. Development 
costs are capitalised only when technical feasibility 
studies identify that the project will deliver future 
economic benefits and these benefits can be measured 
reliably. 

  Development costs have a finite life and are amortised 
on a systematic basis matched to the future economic 
benefits over the useful life of the project.

  The entity’s financial liabilities include trade and other 

Intellectual Property 

payables and borrowings. Financial liabilities are initially 
measured at fair value, and, where applicable, adjusted 
for transaction costs.

  Subsequently, financial liabilities are measured at 

amortised cost using the effective interest method. All 
interest-related charges and, if applicable, changes in 
an instrument’s fair value that are reported in profit or 
loss are included within finance costs or finance income.

  Derecognition 

  Financial assets are derecognised when the contractual 
rights to the cash flows from the financial asset expire, 
or when the financial asset and substantially all the 
risks and rewards are transferred.

  A financial liability is derecognised when it is 

extinguished, discharged, cancelled or expires. 

Impairment 

  The Group recognises an allowance for expected credit 
losses (ECLs) for all debt instruments not held at fair 
value through profit or loss. 

i.  Impairment of Assets

  At each reporting date, the Group reviews the carrying 

values of its tangible and intangible assets to determine 
whether there is any indication that those assets 
have been impaired. If such an indication exists, the 
recoverable amount of the asset, being the higher of 
the asset’s fair value less costs to sell and value in use, 
is compared to the asset’s carrying value. Any excess of 
the asset’s carrying value over its recoverable amount 
is expensed to the statement of profit or loss and other 
comprehensive income.

Impairment testing is performed annually for goodwill 

Intellectual property, which includes trademarks and 
engineering knowledge, is included in the financial 
statements at cost.

Intellectual property and trademarks are only amortised 
or written down where the useful lives are limited or 
impaired by specific circumstances, in such cases 
amortisation is charged on a straight line basis over 
their useful lives and write downs are charged fully when 
incurred.  The directors have assessed the useful life 
of the intellectual property and have determined that it 
has a finite useful life of 10 to 20 years. The intellectual 
property is amortised on a systematic basis matched to 
the expected future economic benefits over the useful 
life of the project. 

k. Foreign Currency Transactions and Balances

  Functional and presentation currency

  The functional currency of each of the group’s entities 

is measured using the currency of the primary 
economic environment in which that entity operates. 
The consolidated financial statements are presented in 
Australian dollars which is the parent entity’s functional 
and presentation currency.

  Transaction and balances

  Foreign currency transactions are translated into 
functional currency using the exchange rates 
prevailing at the date of the transaction. Foreign 
currency monetary items are translated at the year-
end exchange rate. Non-monetary items measured at 
historical cost continue to be carried at the exchange 
rate at the date of the transaction. Non-monetary items 
measured at fair value are reported at the exchange 
rate at the date when fair values were determined.

26

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

  Exchange differences arising on the translation of 

monetary items are recognised in the statement of 
profit or loss and other comprehensive income.

Group companies

  The financial results and position of foreign operations 
whose functional currency is different from the Group’s 
presentation currency are translated as follows:

-  assets and liabilities are translated at year-end 
exchange rates prevailing at that reporting date;

-  income and expenses are translated at average 

exchange rates for the financial year; and

-  retained earnings are translated at the exchange 
rates prevailing at the date of the transaction.

  Exchange differences arising on translation of foreign 

operations are transferred directly to the Group’s foreign 
currency translation reserve in the balance sheet. These 
differences are recognised in the statement of profit or 
loss and other comprehensive income in the period in 
which the operation is disposed. Intercompany loans are 
treated as investments for foreign currency translation 
purposes.

l.  Equity-settled compensation

  The Group operates an employee share option plan 

and performance rights plan. The total amount to be 
expensed over the vesting period is determined by 
reference to the fair value of the options or performance 
rights granted.

m. Comparative Figures

  When required by Accounting Standards, comparative 
figures have been adjusted to conform to changes in 
presentation for the current financial year. 

n. Ordinary shares

  Ordinary shares are classified as equity. Incremental 
costs directly attributable to the issue of ordinary 
shares are recognised as a deduction from equity.

o. New accounting standards and interpretations

  New and amended standards adopted by the Group

  The Group has adopted all of the new and revised 

Standards and Interpretations issued by the Australian 
Accounting Standards Board (the AASB) that are 
relevant to its operations and effective for the current 
year, including AASB 16 Leases. The new and revised 
Standards and amendments thereof and Interpretations 
do not have any material impact on the disclosures or 
on the amounts recognised in the Group's consolidated 
financial statements. 

  AASB 16 Leases – The Group recognises leases using 
the modified retrospective approach and applies the 

low value and short term exemptions in recognising 
leases in its financial statements. Upon application of 
the standard, the Group continues to recognise leases 
as lease expenses in profit or loss. There were no 
changes required to the consolidated financial report to 
recognise the requirements of AASB 16.

Impacts of standards issued but not yet adopted by the 
Group

  The Group has reviewed the new standards issued but 

not yet adopted and does not expect that they will have 
a material impact on the financial statements..

Critical Accounting Estimates and Judgments

The directors evaluate estimates and judgments 
incorporated into the financial report based on historical 
knowledge and best available current information. 
Estimates assume a reasonable expectation of future 
events and are based on current trends and economic 
data, obtained both externally and within the Group.

Key Estimates — Impairment

The Group assesses impairment of finite intangible assets 
and property, plant & equipment at each reporting date 
by evaluating conditions specific to the Group that may 
lead to impairment of assets. At the date of this report 
the Group has sufficient reason to believe that the Group’s 
intangible assets and property, plant & equipment are not 
impaired.

There is a significant risk of actual outcomes being 
different from those forecasted due to changes in 
economic or market conditions and events.

Key Estimates — Share-based payment transactions

The consolidated entity measures the cost of equity 
settled transactions with suppliers and employees by 
reference to the fair value of the equity instruments as 
at the date at which they are granted. The fair value is 
determined using a Black-Scholes model. Refer to Note 
3b for the inputs to the Black-Scholes model.

Key Estimates - Coronavirus (COVID-19) pandemic

Judgement has been exercised in considering the impacts 
that the Coronavirus (COVID-19) pandemic has had, or 
may have, on the consolidated entity based on known 
information. This consideration extends to the nature 
of the activities and geographic regions in which the 
consolidated entity operates. Other than as addressed in 
specific notes, there does not currently appear to be either 
any significant impact upon the financial statements 
or any significant uncertainties with respect to events 
or conditions which may impact the consolidated entity 
unfavourably as at the reporting date or subsequently as a 
result of the Coronavirus (COVID-19) pandemic.

27

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 2: REVENUE

Operating activities

-

-

EdenCrete® sales

OptiBlend® sales and services

Total revenue 

NOTE 3: EMPLOYEE BENEFITS

a.   Employee benefits expense

Expenses recognised for employee benefits are analysed below:

Short-term employee benefits

Post-employment benefits

Share based payments

Total

b.  Share-based Employee Remuneration

2020 
$

2019 
$

1,498,121

928,984

2,427,105

2020 
$

1,614,546

720,355 

2,334,901

2019 
$

(4,813,068)

(4,825,750)

(219,157)

(449,935)

(246,650)

(453,930)

(5,482,160)

(5,526,330)

Included under employee benefits expense in the statement of profit or loss and other comprehensive income is 
$449,395 (2019: $453,930) which relates, in full, to equity settled share-based payment transactions. $111,910 
relates to options (2019: $453,930) and $337,485 relates to performance rights (2019: $nil).

Options

All options granted to personnel are over ordinary shares in Eden Innovations Ltd, which confer a right of one 
ordinary share for every option held. When issued, the shares carry full dividend and voting rights.

Outstanding at the beginning of the year 

Granted 

Exercised

Cancelled/Lapsed

Outstanding at year-end

Exercisable at year-end

2020

2019

Number of Options Weighted Average  

Number of Options Weighted Average  

Exercise Price 
$

Exercise Price 
$

29,859,422

1,000,000

-

(29,529,422)

1,330,000

1,220,000

0.226

0.065

-

0.259

0.111

0.098

36,382,462

0.234

-

-

(6,523,040)

29,859,422

18,383,173

-

-

0.117

0.226

0.226

The options outstanding at 30 June 2020 had a weighted average exercise price of $0.111 and a weighted average 
remaining contractual life of 1.96 years. No options were exercised during the year ended 30 June 2020.

Historical volatility has been the basis used for determining expected share price volatility as it is assumed that this is 
indicative of future tender, which may not eventuate. Volatility of 82-109% and a risk free rate of 0.88-2.24% were used in 
the Black-Scholes models. The life of the options is based on the historical exercise patterns, which may not eventuate in 
the future.

28

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

Performance rights

On various dates during the year, 26,391,012 performance rights with $nil exercise prices were granted to employees. 
Each grant comprised 3 classes. Class A vests upon commercial revenue reaching US$6 million over a rolling 12 month 
period before 31 August 2021, Class B vests upon commercial revenue reaching US$12 million over a rolling 12 month 
period before 31 August 2022 and Class C vests upon commercial revenue reaching US$24 million over a rolling 12 month 
period before 31 August 2023. The value of each right is based on the share price on the date of grant. The values range 
from $0.047 to $0.065 per performance right. 

2020

2019

Number of 
Performance 
Rights

Weighted Average  
Exercise Price 
$

Number of 
Performance 
Rights

Weighted Average  
Exercise Price 
$

Outstanding at the beginning of the year 

Granted 

Exercised or Lapsed

Outstanding at year-end

Exercisable at year-end

-

26,391,012

-

26,391,012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NOTE 4: OTHER FINANCIAL ITEMS 

Foreign exchange gain / (loss)

Impairment expense

Total

2020 
$

29,013

(9,604)

19,409

2019 
$

(8,893)

-

(8,893)

The impairment recognised during the year relates to Hythane Technology rights. The intellectual property for this item 
was fully impaired at year end.

NOTE 5: AUDITORS’ REMUNERATION

Remuneration of the auditor of the parent entity for:

— auditing or reviewing the financial report

— other services

Remuneration of other auditors of subsidiaries for:

— auditing or reviewing the financial report

— other services

NOTE 6: EARNINGS PER SHARE (EPS)

Basic/ Diluted loss per share (cents per shares)

a.

Reconciliation of earnings to profit or loss

Profit/(loss)

Earnings used to calculate basic EPS

2020 
$

40,296

-

64,911

-

2019 
$

50,428

-

56,116

-

2020 
$

2019 
$

(0.5316)

(0.5969)

(9,105,991)

(9,216,320)

(9,105,991)

(9,216,320)

b.

Weighted average number of ordinary shares outstanding during the year used 
in calculating basic EPS

1,712,911,601

1,544,110,867

The options on issue are not potentially dilutive shares. 

29

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 7: INCOME TAX BENEFIT

2020 
$

2019 
$

a.

The prima facie tax on loss from ordinary activities before income tax is 
reconciled to the income tax as follows:

Prima facie tax payable on loss from ordinary activities before income tax 
at 27.5% (2019: 27.5%)  

(2,504,148)

(2,534,488)

Add tax effect of:

—

—

Non-deductible expenses

Current year tax losses not recognised

Less tax effect of:

—

—

Difference in overseas tax rates

Current year temporary differences not recognised

Income tax expense/(benefit)

b.

Components of deferred tax

— 

—

— 

—

— 

— 

Unrecognised deferred tax asset – losses

Property, Plant & Equipment

Capital raising costs

Stock compensation

Provisions and accruals

Intangibles

Total unrecognised deferred tax asset

8,592

7,169

(48,905)

5,932,632

374,410

358,264

2,142,260

(3,837,264)

(27,791)

(73,687)

28,789,044

28,837,949

(1,283,487)

(1,310,200)

170,955

559,544

48,460

307,926

409,985

111,640

(2,710,138)

(2,099,838)

25,574,378

26,257,462

Deferred tax assets have not been brought to account as it is not probable within the immediate future that tax profits will 
be available against which deductible temporary differences and tax losses can be utilised. The benefit of the tax losses 
will only be obtained if the Group complies with conditions imposed by the relevant tax legislation.

NOTE 8: RELATED PARTY TRANSACTIONS  

Transactions between related parties are on normal commercial terms and conditions no more favourable than those 
available to other parties unless otherwise stated. Full details of key management personnel remuneration can be found in 
the remuneration report on page 15.

Key Management Personnel

Management fees paid/payable to Princebrook Pty Ltd, a company in which Mr GH 
Solomon and Mr DH Solomon have an interest. 

Legal fees paid to Solomon Brothers, a firm in which Mr GH Solomon and Mr DH 
Solomon are partners. At year end, no fees were payable (2019: $3,830)

Unsecured interest free loan from Noble Energy Pty Ltd, a Company in which Mr GH 
Solomon and Mr DH Solomon are directors.

2020 
$

2019 
$

281,250

300,000

23,581

79,420

200,000

-

30

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 9: CASH AND CASH EQUIVALENTS

Cash at bank and in hand

Reconciliation of cash

Cash at the end of the financial year as shown in the statement of cash flows is 
reconciled to the consolidated statement of financial position as follows:

Cash and cash equivalents

NOTE 10: INVENTORIES

At cost

NOTE 11: PROPERTY, PLANT AND EQUIPMENT

30 June 2020

Cost

Balance 1 July 2019

Additions

Net exchange differences

Balance 30 June 2020

Depreciation and impairment

Balance 1 July 2019

Depreciation

Net exchange differences

Balance 30 June 2020

Carrying amount at 30 June 2020

2020 
$
1,388,683

1,388,683

2019 
$
3,217,555

3,217,555

1,388,683

1,388,683

3,217,555

3,217,555

2020 
$

701,781

701,781

2019 
$

735,290

735,290

Land and 
buildings

$

Plant and 
equipment

$

Total

$

6,765,183

7,625,077

14,390,260

-

148,534

97,120

170,053

97,120

318,587

6,913,717

7,892,250

14,805,967

(468,224)

(1,458,415)

(1,926,639)

(221,210)

(4,066)

(637,042)

(17,588)

(858,252)

(21,654)

(693,500)

(2,113,045)

(2,806,545)

6,220,217

5,779,205

11,999,422

31

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 11: PROPERTY, PLANT AND EQUIPMENT CONTINUED

30 June 2019

Cost

Balance 1 July 2018

Additions

Transfers

Disposals

Net exchange differences

Balance 30 June 2019

Depreciation and impairment

Balance 1 July 2018

Depreciation

Net exchange differences

Balance 30 June 2019

Carrying amount at 30 June 2019

Land and 
buildings

$

Plant and 
equipment

$

Total

$

4,677,346

1,706,089

7,112,611

11,789,957

445,637

2,151,726

105,114

(105,114)

-

276,634

(92,615)

264,558

-

(92,615)

541,192

6,765,183

7,625,077

14,390,260

(249,149)

(203,859)

(15,216)

(850,424)

(1,099,573)

(552,407)

(55,584)

(756,266)

(70,800)

(468,224)

(1,458,415)

(1,926,639)

6,296,959

6,166,662

12,463,621

Capitalised costs amounting to $97,120 (2019: $1,980,308) have been included in cash flows from investing activities in 
the statement of cash flows for the Consolidated Group.

NOTE 12: INTANGIBLE ASSETS

Intellectual property

Accumulated amortisation

Accumulated impairment expenses

Net carrying value

Balance at the beginning of the year

Additions

Amortisation expense

Impairment

Carrying amount at the end of the year

2020 
$

2019 
$

19,312,548

17,131,915

(1,660,915)

(1,188,807)

(9,428,520)

(9,418,916)

8,223,113

6,524,192

6,524,192

2,180,633

(472,108)

(9,604)

4,907,542

2,068,407

(451,757)

-

8,223,113

6,524,192

Intellectual property relates to pyrolysis technology, EdenCrete®, EdenPlastTM and OptiBlend®. Capitalised costs amounting 
to $2,180,633 (2019: $2,068,407) have been included in cash flows from investing activities in the statement of cash 
flows.

The impairment recognised during the year relates to Hythane Technology rights. The intellectual property for this item 
was fully impaired at year end.

NOTE 13: TRADE AND OTHER PAYABLES

Trade payables and other payables

2020 
$

878,389

878,389

2019 
$

1,069,010

1,069,010

32

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 14: INTEREST BEARING LIABILITIES

Dumont Way property purchase loan (2nd mortgage over the Dumont Way property,  
4% interest rate, denominated in USD and 2.3 years remaining)

Noble Energy Pty Ltd Loan (Unsecured, interest free and denominated in AUD)

SBA Loan (Unsecured, 1% interest rate, denominated in USD and 2 year term)

Total current portion

2020 
$

2019 
$

257,912

247,422

200,000

358,654

816,566

-

-

247,422

Dumont Way property purchase loan (2nd mortgage over the Dumont Way property, 2% 
interest rate, denominated in USD and 2.3 years remaining)

531,401

772,355

SBA Loan (Unsecured, 1% interest rate, denominated in USD and 2 year term)

SnowPoint Loan (Secured over all 3 properties, 11% interest rate, denominated in USD 
and 18 month term with further 6 month option)

Total non-current portion

Total

Opening Balance

Proceeds from borrowing, net of borrowing costs

Repayment of borrowings

Borrowing costs expensed

FX (gain) / loss

Closing balance

* - Non-cash transaction

NOTE 15: PROVISIONS

Provisions for staff entitlements and warranties

563,601

4,086,437

5,181,439

5,998,005

1,019,777

8,125,557

(3,122,254)

293,458

(318,533)

5,998,005

-

-

772,355

1,019,777

1,214,354

116,506*

(355,086)

-

44,003

1,019,777

2020 
$

180,313

180,313

2019 
$

156,954

156,954

33

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 16: ISSUED CAPITAL

a.

Ordinary shares

2020 
No.

2019 
No.

2020 
$

2019 
$

At the beginning of reporting period

1,660,801,742

1,382,990,110

102,636,700

91,230,956

Shares issued during the year

62,794,624

277,811,632

2,867,076

11,405,744

At reporting date

1,723,596,366

1,660,801,742

105,503,776

102,636,700

i.

ii.

The ordinary shares on issue have no par value and there is no limited amount of authorised share capital.

Ordinary shares participate in dividends and in the proceeds on winding up of the parent entity in proportion to 
the number of shares held. At the shareholders meetings each ordinary share is entitled to one vote when a poll is 
called, otherwise each shareholder has one vote on a show of hands.

b.

Options

At the beginning of reporting period

Options issued

Options exercised

Options lapsed

At reporting date

2020 
No.

2019 
No.

111,559,056

215,279,588

1,000,000

81,700,834

-

(138,410,209)

(29,529,422)

(47,011,157)

83,029,634

111,559,056

For information relating to the Eden Innovations Ltd employee option plan, refer to Note 3b Share-based Payments. 

c.

Performance rights

At the beginning of reporting period

Performance rights issued

Performance rights exercised or lapsed

At reporting date

2020 
No.

-

26,391,012

-

26,391,012

2019 
No.

-

-

-

-

For information relating to performance rights granted to directors and employees, refer to Note 3b Share-based 
Payments. 

d.

Capital Management

Management controls the working capital of the Group in order to maximise the return to shareholders and ensure 
that the Group can fund its operations and continue as a going concern. Management effectively manages the 
Group’s capital by assessing the Group’s financial risks and adjusting its capital structure in response to changes 
in these risks and in the market. These responses include the management of expenditure and share issues. There 
have been no changes in the strategy adopted by management to control the capital of the Group since the prior 
year.

NOTE 17: CONTINGENT LIABILITIES AND CONTINGENT ASSETS

The Directors are not aware of any contingent assets or contingent liabilities at 30 June 2020.

34

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 18: CASH FLOW INFORMATION

Reconciliation of Cash Flow from Operations with Loss after Income Tax

Loss after income tax

Non-cash flows in loss

Depreciation and amortisation

Share-based payments expense

Other financial items

Financing costs expensed

Assets written off

Net exchange differences

Changes in assets and liabilities

(Increase)/decrease in trade and other receivables

(Increase)/decrease in inventories

(Increase)/decrease in other current assets

Increase/(decrease) in trade payables and accruals*

Increase/(decrease) in provisions

Increase/(decrease) in other liabilities

Cash flow from operations

* - Net of non-operating movements

NOTE 19: CAPITAL AND LEASING COMMITMENTS

a.

Capital Expenditure Commitments 

— not later than 12 months

— greater than 12 months

b.

Other Commitments

2020 
$

2019 
$

(9,105,991)

(9,216,320)

1,290,148

1,089,362

449,395

9,604

293,458

-

(29,013)

(81,099)

33,509

(39,777)

(208,757)

23,359

(10,526)

601,985

8,893

-

92,615

(26,561)

(5,611)

(117,970)

59,323

404,407

(75,436)

11,327

(7,375,690)

(7,173,986)

2020 
$

2019 
$

-

-

-

-

-

-

The Group had commitments over the next 12 months of approximately $25,750 relating to low-value short-term 
leases.

NOTE 20: RESERVES

a.

Share-based Payment Reserve

The share-based payment reserve records items recognised as expenses on valuation of share options and 
performance rights. Refer to Note 3B for further details of share options and performance rights issued.

b.

Foreign Currency Translation Reserve

The foreign currency translation reserve records exchange differences arising on the translation of foreign 
subsidiaries.

35

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 21: CONTROLLED ENTITIES

a.

Controlled Entities 

Eden Innovations Holdings Pty Ltd (formerly Adamo Energy Ltd)

Eden Innovations (India) Pvt Ltd

Eden Energy Holdings Pty Ltd

Eden Innovations LLC

EdenCrete Industries Inc.

* Percentage of voting power is in proportion to ownership

b.

c.

Acquisition of Controlled Entities

No entities were acquired during the year.

Disposal of Controlled Entities

Country of 

Percentage Owned (%)*

Incorporation

2020

2019

Australia

India

Australia

USA

USA

    -

100

100

100

100

100

100

100

100

100

Eden Innovations Holdings Pty Ltd, a dormant Australian subsidiary, was wound up during the year. 

NOTE 22: PARENT COMPANY INFORMATION

a.

Parent Entity

Assets

Current assets

Non-current assets (includes loans to and investment in subsidiaries of 
$6,135,713)*

Total Assets

Liabilities

Current liabilities

Total liabilities

Equity

Issued Capital

Retained Earnings

Reserves

Share-based payment reserve

Total reserves

Financial performance

Profit / (Loss) for the year

Other comprehensive income, net of tax

Total comprehensive income / (Loss)

2020 
$

2019 
$

112,981

2,610,983

15,990,763

62,991,461

16,103,744

65,602,444

371,232

371,232

234,568

234,568

105,503,776

102,636,701

(98,350,682)

(45,399,552)

8,579,418

8,579,418

8,130,023

8,130,023

(52,951,130)

(2,882,537)

-

-

(52,951,130)

(2,882,537)

* - The loans to and investment in subsidiaries have been assessed for impairment and management recognised an 
impairment expense of $50,374,783 (2019: Nil). It is anticipated that the balance of these loans to and investment in 
subsidiaries will be recovered through the successful commercialisation of EdenCrete® and OptiBlend® by the subsidiary 
companies.

36

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 23: EVENTS AFTER THE BALANCE SHEET DATE

The impact of the Coronavirus (COVID-19) pandemic is ongoing and whilst it has had limited financial impact for the 
Group up to 30 June 2020, it is not practicable to estimate the potential impact, positive or negative, after the reporting 
date. The situation is rapidly developing and is dependent on measures imposed by the Australian Government and other 
countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus 
that may be provided.

On 28 July 2020 151,603,497 fully paid ordinary shares were issued at $0.028 each pursuant to a Share Purchase Plan, 
raising $4,244,898.

On 30 July 2020 2,206,896 fully paid ordinary shares were issued to Mr Stephen Dunmead and Mr Lazaros Nikeas 
pursuant to resolutions passed at the general meeting held on 2 July 2019.

There were no other material events occurring after the reporting date.

NOTE 24: SEGMENT REPORTING

The Group has identified its operating segments based on internal reports that are reviewed and used by the Board of 
Directors (chief operating decision maker) in assessing performance and determining allocation of resources. Activities of 
the Group are managed on Group structure basis and operating segments are therefore determined on the same basis. In 
this regard the following list of reportable segments has been identified.
• 
• 

Eden Innovations LLC – EdenCrete® sales and development and Optiblend® sales, service and manufacturing.
Eden Innovations (India) Pvt Ltd – Optiblend® sales, service and manufacturing in India.

2020

External sales

Internal sales

Total segment revenue

Segment Result

Unallocated expenses

Result from operating activities

Finance costs

Loss before income tax

Income tax benefit

Loss after income tax

Segment assets

Unallocated assets

Total assets

Segment liabilities

Unallocated liabilities

Total liabilities

Capital expenditure

Depreciation and amortisation

Impairment expense

Eden 
Innovations 
LLC

Eden 
Innovations 
India Pvt Ltd

Eliminations

Consolidated 
Entity

$

$

$

$

2,271,499

2,072,757

4,344,256

155,606

-

2,427,105

-

(2,072,757)

-

155,606

(2,072,757)

2,427,105

(5,744,154)

(109,036)

(253,601)

(6,106,791)

14,194,405

276,950

6,619,177

526,972

97,120

818,040

-

-

-

-

(2,549,620)

(8,656,411)

(477,371)

(9,133,782)

27,791

(9,105,991)

14,471,355

8,336,094

22,807,449

7,146,149

(71,212)

7,074,937

97,120

-

-

-

472,108

1,290,148

9,604

9,604

37

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 24: SEGMENT REPORTING CONTINUED

Eden Innovations 
LLC

Eden Innovations 
India Pvt Ltd

Eliminations

Consolidated Entity

$

$

$

$

2019

External sales

Internal sales

Total segment revenue

Segment Result

Unallocated expenses

Result from operating 
activities

Finance costs

Loss before income tax

Income tax benefit

Loss after income tax

Segment assets

Unallocated assets

Total assets

Segment liabilities

Unallocated liabilities

Total liabilities

Capital expenditure

Depreciation and 
amortisation

Impairment expense

2,021,064

1,920,087

3,941,151

(6,060,223)

313,837

-

313,837

98,243

13,839,397

340,364

2,015,006

497,179

2,151,726

726,003

-

-

-

-

-

2,334,901

(1,920,087)

(1,920,087)

(338,571)

-

-

-

363,359

-

-

2,334,901

(6,300,551)

(2,955,289)

(9,255,840)

(34,167)

(9,290,007)

73,687

(9,216,320)

14,179,761

9,134,471

23,314,232

2,512,185

(237,687)

2,274,498

2,151,726

1,089,362

-

38

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDENOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 25: FINANCIAL INSTRUMENTS

a.

Financial Risk Exposures and Management

The main risks the Group is exposed to through its financial instruments are liquidity risk and credit risk.

i.

Liquidity Risk

The Group manages liquidity risk by monitoring forecast cash flows and ensuring that adequate funding is 
maintained. 

The remaining contractual maturities of the Group financial liabilities are:

12 months or less

1 year or more

Total

ii.

Credit risk

2020 
$

1,694,955

5,181,439

6,876,394

2019 
$

1,459,553

772,355

2,231,908

Credit  risk  refers  to  the  risk  that  the  counterparty  will  default  on  its  contractual  obligations  resulting  in  a 
financial loss to the company. The Group has adopted a policy of only dealing with credit worthy counterparties 
and obtaining sufficient collateral or other security where appropriate, as a means of mitigating the risk of 
financial loss from defaults. 

The maximum exposure to credit risk, excluding the value of any collateral or other security, at balance date 
to recognised financial assets, is the carrying amount, net of any provisions for impairment of those assets, 
as disclosed in the balance sheet and notes to the financial statements.

The Group does not have any material credit risk exposure to any single receivable or group of receivables 
under financial instruments entered into by the company.

iii.

Foreign currency risk

The Group is exposed to fluctuations in foreign currencies arising from the sale and purchase of goods and 
services in currencies other than the companies’ functional currency. The risk is measure using sensitivity 
analysis and cash flow forecasting. At 30 June 2020, the effect on the loss and equity as a result of a 10% 
increase in the exchange rates, with all other variables remaining constant would be a decrease in loss by 
$630,000 (2019: decrease of loss of $640,000) and an increase in equity by $460,000 (2019: $600,000). A 
10% decrease in the exchange rates would result in an equal and opposite impact on the loss after tax and 
equity.

iv.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate 
because of changes in market interest rates. The group’s minimal exposure to interest rate risk, the only 
asset / liability affected by changes in market interest rates is Cash and cash equivalents. The Interest 
Bearing Liabilities of the Group are all fixed rate and will not fluctuate because of changes in market interest 
rates.

b.

Financial Instruments

Net Fair Values

The aggregate net fair values of financial assets and financial liabilities, at the balance date, are approximated by 
their carrying values.

39

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

NOTE 26: COMPANY DETAILS

The registered office of the company is:
Eden Innovations Ltd
Level 15
197 St Georges Terrace
Perth Western Australia  6000

The principal place of business is:
Eden Innovations Ltd
Level 15
197 St Georges Terrace
Perth Western Australia  6000

40

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEDIRECTORS’ DECLARATION

In the opinion of the directors of Eden Innovations Ltd:

a. 

the financial statements and notes set out on pages 20 to 40, and the Remuneration disclosures that are contained in 
pages 15 to 17 of the Remuneration Report in the Directors’ Report, are in accordance with the Corporations Act 2001, 
including:

(i)  giving a true and fair view of the Group’s financial position as at 30 June 2020 and of its performance, for the 

financial year ended on that date; and  

(ii)  complying with Australian Accounting Standards (including the Australian Accounting Interpretations) and the 

Corporations Regulations 2001; and

(iii) complying with International Financial Reporting Standards as disclosed in Note 1.

b. 

c. 

the remuneration disclosures that are contained in pages 15 to 17 of the Remuneration Report in the Directors’ 
Report comply with Australian Accounting Standard AASB 124 Related Party Disclosures and

there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and 
payable.

The Directors have been given the declarations required by Section 295A of the Corporations Act 2001 from the Executive 
Chairman and Chief Financial Officer for the financial year ended 30 June 2020.

This declaration is made in accordance with a resolution of the Board of Directors.

_________________________________

Gregory H Solomon

Executive Chairman

Dated this 23rd day of September 2020

41

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
Independent Auditor’s Report to the Members of Eden Innovations Limited 

Report on the Audit of the Financial Report 

Opinion 

We have audited the financial report of Eden Innovations Ltd (the Company and its subsidiaries (the Group)), 
which  comprises  the  consolidated  statement  of  financial  position  as  at  30  June  2020,  the  consolidated 
statement of comprehensive income, the consolidated statement of changes in equity and the consolidated 
statement of cash flows for the year then ended, and notes to the financial statements, including a summary 
of significant accounting policies, and the directors’ declaration.  

In our opinion, the accompanying financial report of the Group is in accordance with the Corporations Act 
2001, including: 

(i)  

giving a true and fair view of the Group’s financial position as at 30 June 2020 and of its performance 
for the year then ended; and 

(ii) 

complying with Australian Accounting Standards and the Corporations Regulations 2001. 

Basis for opinion 

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those 
standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Report section 
of our report. We are independent of the Group in accordance with the auditor independence requirements 
of  the Corporations Act 2001  and  the  ethical  requirements  of  the  Accounting  Professional  and  Ethical 
Standards Board’s APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our 
audit of the financial report in Australia.  We have also fulfilled our other ethical responsibilities in accordance 
with the Code.  

We confirm that the independence declaration required by the Corporations Act 2001, which has been given 
to the directors of the Company, would be in the same terms if given to the directors as at the time of this 
auditor’s report.  

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our 
opinion. 

Material uncertainty relating to going concern 

Without modifying our opinion, we draw attention to Note 1 of the Financial Report, which indicates that the 
Group will require further funding in the next twelve months from the date of this report to fund its planned 
operating costs. These conditions, along with other matters as set forth in Note 1, indicate the existence of 
a material uncertainty that may cast significant doubt about the Group’s ability to continue as a going concern 
and therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course 
of business. 

Key audit matters 

Key audit matters are those matters that, in our professional judgement, were of most significance in our 
audit of the financial report of the current period. These matters were addressed in the context of our audit 
of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate 
opinion on these matters. In addition to the matter described in the Material Uncertainty Related to Going 
Concern  section,  we  have  determined  the  matter  described  below  to  be  the  key  audit  matter  to  be 
communicated in our report. 

42

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
 
 
Key audit matter 

How our audit addressed the key audit 
matter 

Impairment assessment of Intangible 
assets and Plant and equipment 

(Refer to Notes 11 and 12) 

cash  generating  units 

As at 30 June 2020 the Group’s EdenCrete® and 
(CGUs) 
Optiblend® 
comprised  Plant  and  equipment  (P&E)  and 
intangible assets. The carrying values of P&E and 
intangible  assets  as  at  30  June  2020  were, 
respectively,  $5,779,205  (2019:  $6,166,662)  and 
$8,223,113  (2019:  $6,524,192).  Impairment  was 
assessed  by  the  Group  at  the  CGU  level  by 
considering if impairment indicators were present 
as at 30 June 2020. Management determined that 
there were no such indicators of impairment. 

The  impairment  assessment  for  the  Intangible 
assets  and  Plant  and  equipment  is  a  key  audit 
matter due to: 
 

the  significance  of  the  Intangible  assets  and 
Plant and equipment balances to the statement 
of financial position; and 
the  judgement  involved  in  the  impairment 
indicator assessment due to the need to make 
estimates  about  future  events  and  other 
circumstances. 

 

to  evaluate 

the  Group's 

We  performed  the  following  procedures,  among 
impairment 
others, 
assessment: 
  assessed  management’s  determination  of  the 
Group’s CGUs based on our understanding of the 
nature of the Group’s business and the economic 
environment in which the segments operate. We 
also analysed the internal reporting of the Group 
to  assess  how  earnings  streams  are  monitored 
and reported;  

  enquired  of  management  and 

  compared  actual  sales  performance  subsequent 
to year end to forecast sales for the same period; 
inspected  a 
selection of Board of Directors’ meeting minutes 
to assess whether there were any: 
-  observable  indications  that  the  asset  values 
have  declined  during  the  year  significantly 
more than would be expected as a result of 
the passage of time or normal use; 

-  significant changes with an adverse effect on 
the  entity  that  have  taken  place  during  the 
year, or will take place in the near future, in 
the technological, market, economic or legal 
environment  in  which  the  entity  operates  or 
in the market to which an asset is dedicated; 
or 

-  significant changes with an adverse effect on 
the  entity  during  the  year,  or  any  are 
expected to take place in the near future, in 
the extent to which, or manner in which, an 
asset is used or is expected to be used. 

  We also considered whether: 

-  movements in market interest rates or other 
market rates of return on investments during 
the year are likely to affect the discount rate 
used in calculating an asset’s value in use and 
decrease  the  asset’s  recoverable  amount 
materially;  

-  there  was  evidence  of  obsolescence  or 
physical  damage  of  assets  comprising  the 
CGUs; and  

-  the  market  capitalisation  of  the  Group  was 
significantly lower than Eden Innovation’s net 
assets at balance date. 

Other information 

The directors are responsible for the other information. The other information comprises the information in 
Eden  Innovations  Limited’s  annual  report  for  the  year  ended  30  June  2020,  but  does  not  include  the 
consolidated financial report and the auditor’s report thereon. 

Our opinion on the consolidated financial report does not cover the other information and we do not express 
any form of assurance conclusion thereon. 

43

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
 
 
 
 
 
In  connection  with  our  audit  of  the  consolidated  financial  report,  our  responsibility  is  to  read  the  other 
information  and,  in  doing  so,  consider  whether  the  other  information  is  materially  inconsistent  with  the 
financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.  

If, based on the work we have performed, we conclude that there is a material misstatement of the other 
information we are required to report that fact. We have nothing to report in this regard. 

Directors’ responsibility for the financial report 

The directors of the Company are responsible for the preparation of the consolidated financial report that 
gives a true and fair  view in accordance with Australian Accounting Standards and the Corporations Act 
2001 and for such internal control as the directors determine is necessary to enable the preparation of the 
financial report that gives a true and fair view and is free from material misstatement, whether due to fraud 
or error.  

In preparing the consolidated financial report, the directors are responsible for assessing the Group’s ability 
to continue as a going concern, disclosing, as applicable, matters related to going concern and using the 
going  concern  basis  of  accounting  unless  the  directors  either  intend  to  liquidate  the  entity  or  to  cease 
operations, or have no realistic alternative but to do so. 

Auditor’s responsibility for the audit of the financial report 

Our objectives are to obtain reasonable assurance about whether the  financial report  as a whole is free 
from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes 
our  opinion.  Reasonable  assurance  is  a  high  level  of  assurance,  but  is  not  a  guarantee  that  an  audit 
conducted in accordance with the Australian Auditing Standards will always detect a material misstatement 
when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in 
the aggregate, they could reasonably be expected to influence the economic decisions of users taken on 
the basis of this financial report. 

A further description of our responsibilities for the audit of the financial report is located at The Australian 
Auditing and Assurance Standards Board website at: www.auasb.gov.au/auditors_responsibilities/ar2.pdf. 
This description forms part of our auditor’s report. 

Report on the Remuneration Report 

Opinion on the Remuneration Report 

We have audited the Remuneration Report included in pages 15 to 17 of the Directors’ Report for the year 
ended 30 June 2020.  

In our opinion, the Remuneration Report of  Eden Innovations Limited for the year ended  30 June 2020, 
complies with Section 300A of the Corporations Act 2001. 

Responsibilities  

The directors of the Company are responsible for the preparation and presentation of the Remuneration 
Report in accordance with Section 300A of the Corporations Act 2001. Our responsibility is to express an 
opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing 
Standards. 

Nexia Perth Audit Services Pty Ltd 

M. Janse Van Nieuwenhuizen |Director 
Perth 
23 September 2020 

44

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDE 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADDITIONAL INFORMATION FOR LISTED PUBLIC COMPANIES

The following additional information is required by the Australian Securities Exchange Ltd.

1. Shareholding as at 14 September 2020

a.

Distribution of Shareholders

Category (size of holding)

1 – 1,000

1,001 – 5,000

5,001 – 10,000

10,001 – 100,000

100,001 – and over

Number

Ordinary

% Issued 

Capital

237

793

789

3,147

1,961

6,927

0.00%

0.14%

0.34%

6.95%

92.57%

100%

b.

c.

The number of shareholdings held in less than marketable parcels is 2,533.

The names of the substantial shareholders listed in the holding company’s register as at 14 
September 2020 are: 

Shareholder

Noble Energy Pty Ltd

d.

Voting Rights

Number

Ordinary

624,634,707

The voting rights attached to each class of equity security are as follows:

Ordinary shares - Each ordinary share is entitled to one vote when a poll is called, otherwise each 
member present at a meeting or by proxy has one vote on a show of hands.

e.

20 Largest Shareholders — Ordinary Shares

Name

Noble Energy Pty Ltd
Noble Energy Pty Ltd
Arkenstone Pty Ltd 

Citicorp Nominees Pty Ltd
Mr Wayne Kearney & Mrs Robyn Kearney 
Kalsie Holdings Pty Ltd 

1.
2.
3.
4. March Bells Pty Ltd
5. Mr & Mrs Rogerson & Miss C Rogerson 
6.
7.
8.
9. Mr Douglas Solomon
10. Mr Gregory Solomon
11. Miss Michelle Hawksley 
12. Mr Evan Clucas & Ms Leanne Weston 
13. Mr Stephen Carter
14. J P Morgan Nominees Australia Limited
15. Paddocks Superannuation Pty Ltd 
16. Mr Norman Maher
17. Ultimate Site Development Pty Ltd
18. BNP Paribas Noms Pty Ltd
19. Mr John Geelan 
20. HSBC Custody Nominees (Australia) Limited

Number of 
Shares
579,868,477
44,766,230
33,986,707
28,730,343
28,467,652
21,816,204
12,460,313
10,680,610
9,685,942
8,595,007
8,041,316
7,300,000
7,129,564
7,043,621
7,000,000
6,486,864
6,066,381
6,053,232
6,000,000
5,521,447
845,699,910

% Issued  
Capital
30.89%
2.38%
1.81%
1.53%
1.52%
1.16%
0.66%
0.57%
0.52%
0.46%
0.43%
0.39%
0.38%
0.38%
0.37%
0.35%
0.32%
0.32%
0.32%
0.29%
45.05%

45

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEADDITIONAL INFORMATION FOR LISTED PUBLIC COMPANIES

e.

20 Largest Optionholders — EDEOB

Name

Noble Energy Pty Ltd

Mr Julian Merse

Ultimate Site Development Pty Ltd

Mr John Geelan 

Mr Brett Gage

Mr John Jarvis 

Mr & Mrs Weir 

Citicorp Nominees Pty Ltd

Arkenstone Pty Ltd 

1.

2.

3.

4.

5.

6.

7.

8.

9.

10. March Bells Pty Ltd

11. Elysian Islands Pty Ltd 

12. Mr & Mrs Rogerson & Miss C Rogerson 

13. SPO Equities Pty Ltd

14. Philip Elghanian

15. Ricardo Salmon & Leslie Salmon

16. National Nominees Limited

17. Mr Peter McGinty

18. Mr Eddie Sugar

19. Mr Clayton Leslie

20. Mr Daniel Vrabcenjak

Number of 
Options

14,814,815

5,012,804

3,548,490

3,000,000

2,720,000

2,048,416

2,000,000

1,927,856

1,544,851

1,292,289

1,168,926

1,092,594

1,000,000

1,000,000

925,927

925,927

693,500

650,000

600,000

500,000

% of Issued

21.26%

7.19%

5.09%

4.30%

3.90%

2.94%

2.87%

2.77%

2.22%

1.85%

1.68%

1.57%

1.43%

1.43%

1.33%

1.33%

1.00%

0.93%

0.86%

0.72%

46,466,395

66.67%

2.

Unquoted Securities – Options as at 14 September 2020

Holder Name

Date of Expiry

Exercise Price

Employee Share Options

Employee Share Options

Various

Various

30 November 2020

19 December 2022

1 June 2021

1 June 2021

$0.25

$0.065

$0.07

$0.08

3.

Unquoted Securities – Performance rights as at 14 September 2020

Holder Name

Date of Expiry

Vesting

Employee Performance Rights

31 August 2021

US$6m Revenue

Employee Performance Rights

31 August 2022 US$12m Revenue

Employee Performance Rights

31 August 2023 US$24m Revenue

Number  
on issue

330,000

1,000,000

6,000,000

6,000,000

13,330,000

Number  
on issue

8,297,004

8,297,004

8,297,004

24,891,012

Number of  
holders

1

1

3

3

8

Number of  
holders

36

36

36

36

46

Eden Innovations Limited and Controlled Entities ABN 58 109 200 900Annual Report 2020ASX Code: EDEConstruction of EdenCrete® enriched concrete retaining walls on Central 70 project in Denver, Colorado

www.edeninnovations.com